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Abstract 
Dominant mutations in TPM3, encoding α-tropomyosinslow, cause a congenital myopathy 
characterised by generalised muscle weakness. Here, we used a multidisciplinary approach to 
investigate the mechanism of muscle dysfunction in twelve TPM3-myopathy patients. 
We confirm that slow myofibre hypotrophy is a diagnostic hallmark of TPM3-myopathy, and 
is commonly accompanied by skewing of fibre-type ratios (either slow or fast fibre 
predominance). Patient muscle contained normal ratios of the three tropomyosin isoforms and 
normal fibre-type expression of myosins and troponins. Using 2D-PAGE, we demonstrate 
that mutant α-tropomyosinslow was expressed, suggesting muscle dysfunction is due to a 
dominant-negative effect of mutant protein on muscle contraction. Molecular modelling 
suggested mutant α-tropomyosinslow likely impacts actin-tropomyosin interactions and, 
indeed, co-sedimentation assays showed reduced binding of mutant α-tropomyosinslow 
(R168C) to filamentous actin. 
Single fibre contractility studies of patient myofibres revealed marked slow myofibre specific 
abnormalities. At saturating [Ca2+] (pCa 4.5), patient slow fibres produced only 63% of the 
contractile force produced in control slow fibres and had reduced acto-myosin cross-bridge 
cycling kinetics. Importantly, due to reduced Ca2+-sensitivity, at sub-saturating [Ca2+] (pCa 6, 
levels typically released during in vivo contraction) patient slow fibres produced only 26% of 
the force generated by control slow fibres.  
Thus, weakness in TPM3-myopathy patients can be directly attributed to reduced slow fibre 
force at physiological [Ca2+], and impaired acto-myosin cross-bridge cycling kinetics. Fast 
myofibres are spared; however, they appear to be unable to compensate for slow fibre 
dysfunction. Abnormal Ca2+-sensitivity in TPM3-myopathy patients suggests Ca2+-sensitising 
drugs may represent a useful treatment for this condition. 
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Introduction 
Dominant mutations in the TPM3 gene, encoding α-tropomyosinslow (α-TPMslow), cause a 
congenital myopathy characterised by mild to moderate early onset, non-progressive 
generalised muscle weakness (1-3). Axial and respiratory muscles are commonly involved 
and many patients require night-time ventilatory support (1, 2). Recessive mutations, causing 
loss of protein, are rare with only four instances reported to date in patients with relatively 
severe clinical presentations (4-7). In contrast, more than 40 families with dominant TPM3 
missense mutations have been identified involving 19 different residues (1, 3, 7-13), 
Supplementary Tab. 1). Histologically, many TPM3 patients present with slow skeletal 
myofibre hypotrophy in the absence of additional pathological features, resulting in a clinical 
diagnosis of congenital fibre-type disproportion (CFTD) (3). Some patients also exhibit 
nemaline bodies or cores in myofibres and are classified as nemaline myopathy (8) or core 
myopathy (1, 11, 14), respectively. The same mutation in TPM3 can cause a variety of 
histological phenotypes (Supplementary Tab. 1) (1, 3, 7, 14).  
Three tropomyosin isoforms are present in the skeletal muscle sarcomere (15). TPM1 and 
TPM3 encode the two α-tropomyosins exp essed exclusively in fast fibres (TPM1; α-TPMfast, 
Tpm1.st) or slow fibres (TPM3; α-TPMslow, Tpm3.12st), respectively. TPM2 encodes β-
tropomyosin (β-TPM, Tpm2.2st) and is expressed in both fibre types (16, 17). Tropomyosin 
forms alpha-helical coiled-coil heterodimers between one α- and one β-chain. These dimers 
polymerise head-to-tail into a continuous filament that associates along the entire length of 
the actin thin filament and interacts with the troponin complex to regulate Ca2+-mediated 
actin-myosin cross-bridge cycling during muscle contraction. The structure of tropomyosin is 
conferred by a seven residue repeat motive [a-b-c-d-e-f-g] (Fig. 1A and B) (18). Residues at 
positions a and d in the repeat are typically hydrophobic, creating a hydrophobic pocket 
between two tropomyosin chains facilitating dimerisation (blue). Charged residues at 
positions g and e (green) stabilise the dimer through inter-helical salt bridges. Positions b, c 
and f (yellow) localise to the surface of tropomyosin dimers and likely modulate interactions 
with proteins such as actin and troponin.  
 
Many dominant TPM3 mutations (11/19) affect positions b, c or f on the outer surface of the 
dimer (Fig. 1C, yellow). Only five mutations affect positions a and d in the hydrophobic 
pocket (Fig. 1C, blue) and three mutations affect positions g and e constituting the inter-
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helical salt bridges (Fig. 1C, green). All mutations fall within, or very close to, one of the 
seven actin binding regions of tropomyosin (Fig. 1C, purple shaded area of the molecule) 
(19). In particular, there is a striking concentration of mutations within the fifth actin-binding 
region of α-TPMslow (R168H, R168G, R168C, K169E, E174A) some of which are recurrent 
in several unrelated families (e.g. R168 residue is mutated in 20 different families). 
Although the structure and function of tropomyosin is well established, the mechanism(s) by 
which mutations in TPM3 cause muscle weakness remains poorly understood. Two recent 
studies showed that four patients with dominant TPM3 mutations had abnormal cross-bridge 
cycling kinetics and Ca2+-sensitivity of contraction in single skeletal myofibres isolated from 
patient biopsies [n=3 (20), n=1 (21)]. However, these studies were limited by small sample 
sizes, and separate assessment of the properties of slow versus fast myofibres was only 
possible to a limited extend. In this study, we aimed to unravel the mechanism of muscle 
weakness in a cohort of 12 patients with dominant TPM3 mutations. We performed thorough 
histological characterisation, assessed thin filament protein expression and quantified the 
contractile properties of single myofibres isolated from patient muscle specimens (10/12 
patients, Tab. 1). 
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Results 
TPM3-myopathy patients have slow fibre hypotrophy and deregulation of slow and 
fast muscle fibre proportions 
The main histological characteristic in all patients with TPM3 mutations is selective 
hypotrophy of slow-twitch type-1 fibres, compared to fast-twitch type-2 fibres (1, 3, 7) (Fig. 
2A, ATPase pH 4.6, slow myofibres appear dark; see Supplementary Tab. 2 for 
measurements). On average, fast fibres were between 1.7 and 5.2 times larger in diameter 
than slow fibres (Fig. 2B), corresponding to a %FSD of 41 % - 78.3 % (Fig. 2C). The 
selective hypotrophy of slow fibres in TPM3 patients is consistent with the slow-fibre 
specific expression of α-TPMslow. 
Additionally, fibre-typing was skewed in patient biopsies, either towards fast fibre 
predominance (five patients, less than 30 % slow fibre area) or slow fibre predominance (six 
patients, more than 60 % slow fibre area), compared to age-matched control biopsies where 
the CSA occupied by either fibre-type is approximately 50:50 [this study and (22, 23)] (Fig. 
2D). Only one patient biopsy show d normal slow-fast fibre distribution (between 40-60 % 
slow fibre area). 
 
Tropomyosin isoform ratios are not commonly altered in TPM3-myopathy patients  
In normal muscle, the ratio of α/β tropomyosin molecules is approximately 50:50 β-TPM/α-
TPMfast in fast fibres and 50:50 β-TPM/α-TPMslow in slow fibres (24). A patient and 
transgenic mouse model carrying the TPM3 M9R mutation, the first mutation associated with 
nemaline myopathy, showed an imbalance of this ratio, with a dramatic excess of α-TPMslow 
relative to β-TPM in skeletal muscle (25) (Fig. 3Ai, Lane 5). This disruption in tropomyosin 
stoichiometry was proposed as a potential mechanism of muscle weakness (25). In contrast, 
in this cohort of 12 TPM3-myopathy patients, we observed normal ratios of α/β tropomyosin, 
similar to controls (Fig. 3Ai). The scatter plots in Fig. 3Aii-iiii show the relative levels of 
each tropomyosin isoform relative to the type-1 fibre CSA, as determined by ATPase 
staining. β-TPM is present at equal amounts in slow and fast myofibres in all samples (~50 % 
of total tropomyosin, Fig. 3Aii). The relative expression of α-TPMslow and α-TPMfast 
correlates well with type-1 fibre CSA (positive correlation for α-TPMslow and negative 
correlation for α-TPMfast, Fig. 3Aiii and 3Aiiii). The linear regression slope fitted to the data 
was not significantly different between patients and controls, demonstrating a normal ratio of 
α/β tropomyosin isoforms in fast and slow fibres. 
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Mutant α-TPMslow is expressed in muscle of TPM3-myopathy patients 
The autosomal dominant inheritance of TPM3 mutations within our cohort is consistent with 
the hypothesis that mutant α-TPMslow is expressed in slow skeletal myofibres and causes 
disease via a dominant-negative effect on thin filament function. To confirm mutant α-
TPMslow is present in patient muscle, we isolated the filamentous fractions (representing 
proteins incorporated in high-molecular weight structures such as sarcomeres) and performed 
2D-SDS-PAGE. Five patients in our cohort from whom skeletal muscle samples were 
available, had a mutation that resulted in an amino-acid substitutions affecting a charged 
residue leading to a predicted alteration in the isoelectric point (pI) of α-TPMslow. Thus, 
isoelectric focusing allowed us to separate the mutant from the wild-type protein on the basis 
of charge in these patients, and the second dimension urea-SDS gel separated the three 
tropomyosin isoforms from each other. The mutant α-TPMslow protein could then be observed 
as a left-sided (Fig. 3B; R186G, R91P, K169E, R168C) or right-sided shift (Fig. 3B, E241K) 
from the wild-type α-TPMslow and was present in all patient muscles. The total pool of α-
TPMslow (both wild-type and mutant isoforms) correlated with the slow fibre CSA (% type-1 
fibre area annotated above each blot, se  Supplementary Tab. 2 for measurements). However, 
mutant α-TPMslow was less abundant compared to wild-type, ranging from 27 to 45 % of total 
α-TPMslow (% mutant α-TPMslow annotated on each blot).  
 
The actin-binding properties of K169E and R168C mutant α-TPMslow proteins are 
altered 
The position of many TPM3 mutations within or close to actin binding sites suggest most 
mutations may influence interactions between α-TPMslow and actin filaments. Therefore, we 
performed actin-tropomyosin co-sedimentation assays with two recombinant mutant α-
TPMslow proteins (R168C and K169E) and compared their actin binding properties to wild-
type α-TPMslow. These mutations were chosen because they are both located in the fifth actin 
binding domain, the area that harbours a hotspot for myopathy causing mutations, and affect 
amino acids predicted to be involved in actin interactions. We co-sedimented incremental 
amounts of each of the three α-TPMslow proteins with 100 nM filamentous skeletal actin. Fig. 
4A shows a representative SDS-PAGE of the filamentous fraction isolated following 
ultracentrifugation, demonstrating dose-dependent binding of wild-type α-TPMslow to actin 
filaments. Densitometry data of the bound fraction versus the total amount of α-TPMslow 
added to the reaction was fitted to a Hill equation, to determine the binding constant Kd and 
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the Hill coefficient (h) for all three α-TPMslow proteins (Fig. 4B). The α-TPMslow R168C 
protein showed reduced actin binding affinity compared to wild-type or the α-TPMslow K169E 
protein (Kd = 771.4±188.6 nM for R168C, 180.2±37.6 nM for wild-type and 164.0±110.6 nM 
for K169E, range represents 95% confidence interval). The Hill coefficient was similar in all 
three mutations (h = wild-type 4.471±3.0, R168C 3.308±2.4, K169E 1.602±1.3). These 
results suggest actin binding may be the mechanism by which the TPM3 R168C mutation 
alters contractile function and causes muscle weakness. 
 
Fast fibre specific α-actinin-3 is ectopically expressed in slow fibres of patients with 
R168H/G TPM3 mutations 
As many TPM3 patient biopsies displayed a skewing to either slow- or fast- fibre 
predominance by ATPase stain, we stained serial muscle sections with antibodies recognizing 
fibre-type specific isoforms of MHC, troponin and α-actinin to investigate whether the 
expression of several fibre-type-specific proteins was normal (Fig. 5A, Supplementary Fig. 
1). Three patients (Patients 4, 6a and 6b, each with R168 substitutions), showed elevated 
levels of hybrid fibres expressing both slow and fast myosin isoforms. All other patients 
showed normal fibre profiling of myosin and troponin. Curiously, when further 
characterizing the expression profile of hybrid fibres in Patients 4, 6a, 6b and 10, we 
observed ectopic expression of α-actinin-3 in dedicated slow fibres as determined by the 
expression of myosin and troponin (Fig. 5A, Supplementary Fig. 1). α-Actinin-3 is a 
component of the Z-disc normally present in fast myofibres and has been found to be 
important for muscle performance (strength and speed) (26, 27). Our results suggest that the 
restricted fibre-type expression profiles of α-actinin-2 and -3 is differently regulated to 
myosin, troponin and tropomyosin in patients with TPM3 mutations compared to age-
matched controls. 
 
Phosphorylation of tropomyosin is increased in patients with mutations in TPM3 
In normal skeletal muscle, a proportion of both α- and β-TPM is phosphorylated at residue 
S283 (28, 29)(Fig. 5Bi). The effect of tropomyosin phosphorylation in skeletal muscle is 
poorly understood, but studies suggest it is important for tropomyosin function by enhancing 
head-to-tail interactions and increasing the cooperative activation of myosin resulting in 
enhanced force production (30). We investigated whether phosphorylation at S283 was 
altered in TPM3 patients (as a possible contributor to muscle dysfunction) by Western blot 
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analysis using an anti-phosphor-S283 specific antibody (Fig. 5Bii shows a representative 
Western blot). Phosphorylation of tropomyosin (all three isoforms were analysed in 
combination) was increased in 6/8 of patients with samples available for analysis, compared 
to five age-matched controls (Fig. 5Biii). However, elevated levels of S283 phosphorylation 
were also observed in patients with mutations in TPM2, ACTA1, DNM2, DMD and DYSF 
(Fig. 5Biiii).  
 
Mutations in DMD (causing Duchenne and Becker muscular dystrophy) and DYSF (causing 
limb girdle muscular dystrophy type-2B) cause muscle fibre breakdown and regeneration. It 
is well documented that tropomyosin phosphorylation is higher during development in 
animals (29), and thus we explored whether increased phosphor-S283 in dystrophic muscle 
was related to fibre re-generation. Using IHC analysis, we established that phospho-S283 
tropomyosin levels did not correlate with fibre-type or with fibre re-generation in control or 
patient biopsies (Supplementary Fig. 2B-C). In TPM3 patients however, levels of phospho-
S283 tropomyosin were specifically elevated in small, slow-twitch myofibres (Supplementary 
Fig. 2A). This suggests that increased phosphorylation of tropomyosin is not specific to 
TPM3 disease, but may be a compensatory response to muscle dysfunction due to a variety of 
mechanisms. 
 
Slow myofibres of TPM3-myopathy patients have reduced maximal force, likely due 
to altered cross-bridge cycling 
In order to understand how muscle weakness develops in TPM3 patients we performed 
contractile studies on single, chemically-permeabilised patient myofibres or small fibre 
bundles by immersing them in Ca2+-containing solutions (see methods regarding details for 
analysis of bundles). This induces activation of the contractile filaments allowing 
measurement of isometric force production. 
 
First, fibres and fibre bundles were activated at saturating [Ca2+] of pCa 4.5 (~31.6 µM) to 
induce maximal isometric contraction (Fmax, Fig. 6A). A small but significant force deficit 
was observed in slow myofibres and fibre bundles from seven of 10 TPM3-myopathy patients 
compared to pooled control samples (Fmax in all TPM3 patients ranges from 52.17 – 116 
mN/mm2 compared to 143.1±31.8 mN/mm2 in controls, *p<0.01 one-way ANOVA, Fig. 6C 
and D). This force deficit was present despite normalization to the smaller CSA in slow fibres 
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of TPM3 patients. Fmax in type-2 fibres was not different from control fibres (106.7-186.7 
mN/mm2 in patient fibres and 147.7±29.34 mN/mm2 in control fibres) (Fig. 6B). In bundles, 
Fmax was lower in bundles with higher slow MHC content in two of three patients 
(Supplementary Fig. 3).  
 
During muscle contraction, a cyclic interaction between the myosin heads and thin filaments, 
followed by a conformational change in myosin, allows the filaments to slide past each other. 
Correct positioning of tropomyosin on actin filaments during the various stages of myosin-
actin interactions is crucial for efficient cross-bridge cycling. To determine if the force deficit 
in slow myofibres of TPM3 patients can be attributed to changes in cross-bridge cycling 
kinetics we measured the rate of tension re-development (Ktr) during maximal activation, 
after a short period of unloaded shortening following by re-stretch (a typical length and force 
trace are presented in Fig. 7Ai). The speed of cross-bridge cycling is physiologically faster in 
type-2 (fast-twitch) fibres compared to type-1 (slow-twitch) fibres (see controls in Fig. 7Aii-
iii). Slow fibres from eight of 10 TPM3 patient biopsies displayed a significant reduction in 
Ktr compared to controls (Ktr in all TPM3 patients ranges from 0.758-1.217 s
-1 compared to 
1.493±0.25 s-1 in controls, *** p<0.0001, * p<0.01, one-way ANOVA, Fig. 7Aii), whereas 
fast myofibres were not different from control myofibres (Fig. 7Aiii). These results suggest 
that myosin cross-bridge cycling kinetics are altered in slow fibres of TPM3 patients, 
contributing to muscle weakness by reducing the fraction of strongly bound cross-bridges 
during activation. 
 
Fmax is proportional to the force generated by a single strongly bound actin-myosin cross-
bridge and the fraction of myosin heads attached to actin. We assessed active stiffness in 
TPM3 biopsies, a measure proportional to the number of myosin heads strongly attached to 
actin during an isometric contraction (31), to study whether this contributes to muscle 
weakness. We measured active stiffness by performing fast length changes in isometrically 
contracted single myofibres (typical length/force traces are presented in Supplementary Fig. 4 
and a typical patient and control plot of the length change (∆L) versus force change (∆F) is 
presented in Fig. 7Bi and ii, respectively)(32). We observed a trend towards reduced absolute 
active stiffness in type-1 fibres and bundles/hybrid fibres of most TPM3 patients (Fig. 7Biii 
and iiii), which was not present in type-2 fibres (Fig. 7Bv). The change in active stiffness was 
proportional to Fmax, as the difference was not present when stiffness was normalised to 
Fmax (Fig. 7Bvi-viii). Since stiffness is proportional to the number of strongly attached 
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myosin cross-bridges, a reduction of active stiffness proportional to force reduction suggests 
that forces per cross-bridge were normal, but, in line with the reduced Ktr, the number of 
strongly attached cross-bridges may be reduced in slow fibres of TPM3 patients, likely 
contributing to muscle weakness. 
 
Ca
2+
-sensitivity of contraction and maximal contractile force are decreased in 
patients with TPM3 mutations 
Tropomyosin and the troponin complex are pivotal in regulating Ca2+-induced cross-bridge 
cycling during muscle contraction. We assessed the sensitivity to Ca2+ of permeabilised 
fibres, by bathing preparations in incrementally increasing [Ca2+] (pCa 6.2-4.5) and 
measuring the generated contractile force. In slow myofibres and fibre bundles/hybrid fibres 
of all patients, the force-pCa curves were shifted to the right compared to controls (Fig. 8Ai-
ii). As a result, the pCa50, representing the negative logarithm of the [Ca
2+] at which 
preparations produce 50 % of their Fmax, was significantly reduced in type-1 fibres and 
bundles/hybrid fibres from all patients compared to controls (pCa50 type-1: 5.96±0.06 
controls, 5.69±0.04 patients; pCa50 bundles/hybrid:  5.99±0.09 controls, 5.67±0.05 patient, 
Fig. 8Bi-ii). This result indicates that more Ca2+ was required in patient biopsies than control 
biopsies to achieve the same relative force. In contrast, fast fibres from patients and controls 
showed normal Ca2+-activated force production (Fig. 8Aiii, Fig. 8Biii). 
 
Our data demonstrates that slow fibres and in bundles/hybrid fibres from patients with TPM3 
mutations produce on average ~ 63 % of the force produced by control fibres at saturating 
[Ca2+] (pCA 4.5). During a maximal contraction the intracellular [Ca2+] can rise from resting 
levels of ~0.1 µM (pCa 7) to ~10 µM (pCa 5) (33). However, myofibres in vivo rarely 
undergo maximal stimulation and mostly operate at sub-maximal levels, typically resulting in 
[Ca2+] of around 1-5 µM) in type-1 fibres (yellow area in Fig. 8A) (34-36). At these 
physiological Ca2+ levels (pCa 6.0), slow fibres and bundles/hybrid fibres from TPM3 
patients produce on average only 26 % of the force produced by control slow fibres and 
bundles/hybrid fibres (Fig. 8Ci-ii), whereas patient fast fibres produce forces similar to 
controls (Fig. 8Ciii). Thus, our results suggest reduced Ca2+-sensitivity is a significant basis 
for muscle weakness in TPM3-myopathy. 
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Ectopic α-actinin-3 expression in slow myofibres does not correlate with increased 
maximal force 
Four patients with TPM3 mutations at R168 displayed ectopic expression of α-actinin-3 in 
slow myofibres. Since α-actinin-3 expression is associated with increased muscle strength 
and speed (26, 27) we determined whether α-actinin-3 in slow fibres may influence 
contractile properties. We tested if α-actinin-3 expression was more commonly observed in 
fibres with higher Fmax in eight fibres from two patients. However, we found no correlation 
between ectopic α-actinin-3 and force production in these patient fibres (Supplementary Fig. 
5).  
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Discussion 
Mutations in TPM3 cause a range of histopathological patterns and are associated with 
generalised muscle weakness. To date, the cause of muscle dysfunction is not well 
understood in these patients, hindering the development of evidence-based treatments for 
TPM3-myopathies. Thus, we performed extensive phenotypical and functional 
characterization of a large cohort of TPM3-myopathy patients to understand the molecular 
mechanism(s) of their muscle weakness. 
 
The main histological feature of TPM3-myopathy patients in this cohort, and other published 
cohorts (1-3), was a selective hypotrophy of slow myofibres, while other histological features 
such as nemaline rods and caps were rarely present (four of 15 patients). The selective 
hypotrophy and contractile dysfunction of slow myofibres is consistent with the restricted 
slow-fibre expression of α-TPMslow, the main protein expressed from TPM3 in skeletal 
muscle. We confirmed the presence of mutant α-TPMslow in the filamentous fraction of 
patient skeletal muscle via 2D-SDS-PAGE for patients possessing a TPM3 mutation resulting 
in a charge change. In patients with protein aggregates (e.g. nemaline bodies), it has been 
uncertain whether mutant protein is actually incorporated into the sarcomere, or partitions 
into protein aggregates within the muscle fibre. In our study, protein aggregates were not 
observed in biopsies analysed by 2D-SDS-PAGE, suggesting that α-TPMslow mutant protein 
is likely incorporated into sarcomeres causing muscle weakness via a dominant negative 
effect on contractile function. 
Muscle contraction and force production rely on efficient interactions between tropomyosin 
polymers and major binding partners, the troponins and the actin filament, in response to 
Ca2+-influx. In this series of twelve muscle biopsies from TPM3-myopathy patients, we 
showed normal fibre-type expression of the major contractile proteins myosin, actin, troponin 
and tropomyosin. Furthermore, we confirmed normal ratios of the three skeletal muscle 
tropomyosin isoforms according to fibre-type composition for all patients. Our data suggest 
the higher relative abundance of α-TPMslow previously reported in a patient bearing a M9R 
substitution in TPM3 (25, 37) may be a specific property of this mutation, perhaps related to 
its position within the dimerisation domain. In a small number of patients, we observed 
ectopic expression of the fast fibre Z-disc protein α-actinin-3 in slow myofibres. The 
consequence of slow-fibre expression of the fast-fibre α-actinin-3 is not clear, and may relate 
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to both metabolic and structural roles of a-actinin-3, though we excluded an overt effect on 
contractile force of single myofibres. 
We investigated tropomyosin phosphorylation at residue S283 in our cohort. Tropomyosin 
phosphorylation has mainly been studied in the context of cardiac function (38-41) and to the 
best of our knowledge has not been investigated in skeletal myopathy patients. In vitro 
studies suggest phosphorylation strongly affects tropomyosin properties [e.g. stronger head-
to-tail interaction, enhanced troponin binding, higher myosin ATPase activity and long-range 
cooperative activation of myosin-thin filament binding (30, 42, 43)]. We showed 
tropomyosin phosphorylation was commonly increased in a wide range of genetic muscle 
disorders including TPM3-myopathy. However, the cause of this up-regulation and the effect 
on skeletal muscle contractility is unclear. The p38-MAPK (mitogene-activated protein 
kinase) and ERK (extracellular signal-related kinase) signalling pathways are likely involved 
in tropomyosin phosphorylation of cardiac muscle and non-muscle cells, respectively (44-
46). In skeletal muscle, these pathways regulate exercise-induced adaptive responses on gene 
expression (reviewed in 47), suggesting tropomyosin phosphorylation may be involved in 
remodelling or adaptation to cellular stress.  
Most reported TPM3 substitutions lie within or near actin-binding domains, with several 
substitutions believed to influence direct electrostatic interactions with actin in the “off” state 
[when tropomyosin blocks myosin binding sites on the actin filament e.g. R91, R168, R245 
directly interact with actin D25 (48-50)]. Our data and previous studies have shown that 
many tropomyosin substitutions indeed affect binding to actin-filaments (51-54). Thus, 
altered actin-binding likely represents a common mechanism by which tropomyosin mutants 
alter sarcomeric function, perhaps related to the Ca2+-activated movement of tropomyosin 
between the “on” and “off” position during cross-bridge cycling (50, discussed in 55). 
 
Recent studies have attempted to predict the effect of mutations on actin-tropomyosin 
interactions and the resulting contractile abnormality, classifying them as “gain-of-function” 
changes (hyper-contractile phenotype, shift towards “on” state) and “loss-of-function” 
changes (hypo-contractile phenotype, stabilizing the “off” state) (49, 56, 57). Most mutations 
in our cohort are predicted to cause a “loss-of-function” (e.g. decreased Ca2+-sensitivity and a 
hypocontractile phenotype). The only exception is TPM3 K169E, predicted to favour the 
“on” position and enhance myosin-actin binding (49, 56)]. This phenotype was confirmed in 
reconstituted thin filaments in vitro (49). However, isolated slow myofibres and fibre bundles 
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of all TPM3 patients (including Patient 1 carrying the K169E mutation), showed reduced 
Ca2+-sensitivity of contraction. Our data are consistent with the patient phenotype described 
in (1) and do not support the hyper-contractile phenotype of the K169E mutation present in in 
vitro assessment of isolated filaments (49). This discrepancy may be explained by the greater 
complexity of single-fibre contractility studies, a setting that evaluates the combined 
contributions of actin, tropomyosin and troponin binding and regulatory proteins within a 
mature myofibre, which may also have undergone adaptive responses to disease. These may 
not be mirrored by in vitro actin motility studies or predictions via molecular modelling. 
Additional factors, such as interactions with other sarcomeric proteins like the troponin 
complex (58), may also contribute. Additionally, a recurrent mutation in TPM3, R168H, was 
found to reduce [current study and (21)] or increase Ca2+-sensitivity (20) in different patients 
with the same mutation. The cause for this patient to patient variability remains to be 
established. 
In our study, we identified two major abnormalities in contractile performance that we 
believe directly underpins weakness in TPM3-myopathy. Firstly, all patients exhibited 
reduced Ca2+-sensitivity of contraction in slow myofibres, likely resulting in a significant 
reduction in the contractile force generated at physiological, sub-maximal activation of 
muscle. Secondly, slow myofibres demonstrated a significant reduction in cross-bridge 
cycling kinetics and a small reduction in active stiffness (assesses the number of strongly 
bound myosin-actin cross-bridges) – meaning that myosin less effectively and less stably 
transits along actin filaments during contraction.  Collectively, these two abnormalities likely 
cause insufficient force production during a normal action potential resulting in slow fibre 
weakness.   
The selective dysfunction of slow myofibres in our cohort demonstrates the importance of 
assessing the two fibre types separately, and raises the question as to why fast myofibres are 
not able to compensate for dysfunctional slow myofibres. Inherent differences exist between 
the two fibre types. Slow myofibres are less fatigable than fast myofibres, probably due at 
least in part to larger numbers of mitochondria and a greater capacity for oxidative 
metabolism (59, 60). Additionally, fast myofibres have a higher ATP consumption. Particular 
muscle groups, such as respiratory muscles, rely on slow fibres to produce sustained, low 
intensity contractions. Substantial weakness of respiratory muscles is common in TPM3 
patients, and effective treatments that specifically target slow muscle fibre dysfunction may 
ameliorate respiratory insufficiency. 
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In summary, contractile function was commonly impaired in TPM3-myopathy patients. In 
particular, we showed reduced force generation caused by altered cross-bridge cycling 
kinetics and reduced Ca2+-sensitivity of muscle contraction. The identification of abnormal 
Ca2+-sensitivity suggests the use of Ca2+-sensitisers may present a viable therapeutic 
approach for TPM-related myopathies. To date, a number of agents are known to be effective 
at improving Ca2+-sensitivity in isolated skeletal myofibres from various species including 
bovine, human, mouse and rabbit (21, 61-64). Additionally, Ca2+-sensitisers were able to 
ameliorate muscle dysfunction in a rat model of myasthenia gravis (61) and isolated skeletal 
myofibres from congenital myopathy patients with mutations in TPM3, TPM2 and NEB (21, 
62). This therapeutic approach appears to be promising; however, most of these agents target 
the fast troponin isoforms and are unlikely to ameliorate slow fibre dysfunction. A Ca2+-
sensitiser acting on slow skeletal/cardiac troponin-C did not improve Ca2+-sensitivity in 
skeletal myofibres in a recent study, suggesting that new compounds targeting slow myofibre 
dysfunction have yet to be developed (65). Also, it appears that TPM2 and TPM3 mutations 
can either increase or decrease Ca2+-sensitivity in a patient and mutation-specific manner 
(overview in Supplementary Tab. 4), thus Ca2+-sensitisers will only be useful in a subset of 
patients. Patients with increased Ca2+-sensitivity display a hyper-contractile clinical 
phenotype (21, 53), suggesting treatment with Ca2+-sensitisers must be tightly regulated to 
ensure appropriate muscle function and avoid side effects. 
Materials and Methods 
Study approval 
This study was approved by the human ethics committees of the Stollery Children’s Hospital, 
Edmonton, Canada (ID: 5856), Royal Children’s Hospital, Melbourne, Australia (ID: 
21102A), Children’s Hospital at Westmead, Sydney, Australia (ID: 2000/068, 10.CHW.45), 
University of Sydney, Australia (ID: 01/11/50) and Boston Children’s Hospital Institutional 
Review Board (03-08-128R). Informed consent was obtained from all individuals. 
Molecular modelling 
Molecular modelling was based on the 7 Ångstroms resolution crystal structure of an α-
TPMfast dimer isolated from adult porcine ventricles (RCSB Protein Data Bank 1C1G, 
Whitby and Phillips (23)). Molecular graphics were created with Swiss-PDB Viewer v4.1.0 
(66). 
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Antibodies 
Mouse anti-sarcomeric actin (5C5, 1:100 for immunohistochemistry [IHC] and 1:10000 for 
Western blot), fast myosin [MY32, 1:800 for IHC, tropomyosin (TM311, 1:20,000 for 
Western blot and 1:800 for IHC), troponin-Tfast (TNNT3, 1:30 for IHC and 1:1000 for 
Western blot) were obtained from Sigma Aldrich. S283-phosphorylated tropomyosin was 
detected using the rabbit anti-Tm-pS283-050 (1:500 for Western blot and 1:30 for IHC, 21st 
Century Biochemicals) and slow myosin antibodies were obtained from Chemicon (1:800 for 
IHC and 1:7000 for Western blot). Polyclonal α-actinin-3 antibodies were produced in-house 
(antibody 5B3 diluted 1:50 for IHC and antibody 5A2 1:1500 for Western blot) (67). 
Troponin-Islow (MYNT-S, diluted 1:10 for IHC) and fast (MYNT-F, diluted 1:150) 
antibodies were kindly supplied by Takeshi Nakamura, Japan. Troponin-Tslow antibodies 
(CT3) were obtained from the Developmental Studies Hybridoma Bank, University of Iowa 
(diluted 1:50 for IHC). Cardiac actin and neonatal myosin heavy chain (MHC) antibodies 
were obtained from American Research Products Inc, USA and Novocastra Laboratories Ltd, 
UK, respectively. 
 
IHC and Zenon labelling  
IHC was performed as described previously (68). Sections were either fixed as described in 
(37) (MYNT-S) or for 10 min in 3% PFA (MYNT-F, CT3 and TNNT3) or used unfixed 
(other antibodies). A Zenon mouse IgG labelling kit (Molecular Probes) was used to directly 
label primary antibodies with different fluorophores for co-staining with two mouse 
antibodies as per manufacturer’s instructions (either MHC type-2A and type-1 [Fig. 5] or 
neonatal MHC and cardiac actin [Supplementary Fig. 2C]). Staining was imaged using 
standard fluorescence microscopy. 
 
Fibre morphometry 
Fibre morphometry was performed on cryo-sections stained for myosin ATPase (69)] or 
following IHC for MHC isoforms. At least 200 fibres, visible in two distant fields of the same 
section were analysed using ImagePro Plus 4 software (Media Cybernetics). The greatest 
distance between opposite sides of the narrowest aspect, the MinFeret diameter, was 
measured to obtain the fibre diameter from a cross sectional cut. The percentage fibre-size 
disproportion (%FSD) was calculated as described in (1) and slow fibre area was calculated 
assuming circular shape of myofibres. 
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Western blot and 2D-polyacrylamide gel electrophoresis (2D-SDS-PAGE) 
Western blot methods were based on (70) and tropomyosin isoforms were resolved as 
described in (53). Extraction of the filamentous protein pool from skeletal muscle sections 
and 2D-SDS-PAGE to determine mutant tropomyosin expression were performed as 
described previously (14, 71). 
 
Protein sources and actin-tropomyosin co-sedimentation 
We employed site-directed mutagenesis to produce wild-type and mutant (R168C, K169E) α-
TPMslow baculoviruses to infect Sf9 insect cells using the baculovirus expression method as 
described previously (72, 73). 
Filamentous actin was prepared from actin-acetone powder isolated from rabbit muscle (74) 
and a 1 µM stock with 1 µM phalloidin and 0.1 mM ATP was used for experiments.  
All protein stocks were prepared in and dialyzed against a buffer containing 100 mM KCl, 50 
mM Imidazole, 8 mM MgCl2, 2 mM EDTA, 10 mM DTT and 0.5 mg/mL ultrapure bovine 
serum albumin (BSA, Sigma). Ten µM tropomyosin stocks were cleared of aggregates by 
ultracentrifugation at 603,180 x g (Sorvall M120-SE centrifuge, S100AT6-0199 rotor) for 20 
min at 4 °C. Ten nM actin were co-sedimented with incremental amounts of tropomyosin 
(50-1000 nM) in 1 mL reaction volume at 51,427 x g for 1.5 hr at 25 °C (Sorvall Evolution 
RC centrifuge, F20-Micro rotor) in siliconised polypropylene tubes. The pelleted fractions 
were solubilised in loading buffer and loaded on 4-15 % Criterion TGX gels (Biorad). 
Densitometry analysis on actin and tropomyosin bands was performed using GeneTools 4.0 
software (Synoptics Ltd). Values were corrected for sedimentation in the absence of actin and 
plotted as the ratio tropomyosin/actin vs. total [tropomyosin] added. Data were fitted to a Hill 
equation to determine the binding constant Kd and Hill’s coefficient h using GraphPad, Prism 
(Version 5.01). 
Contractile measurement of myofibres isolated from frozen human muscle biopsies 
Small fractions of frozen muscle biopsies were thawed as described previously (62) in a 
solution containing 50 % glycerol and 50 % Ca2+-free relaxing-solution (100 mM BES, 6.97 
mM EGTA, 6.48 mM MgCl2, 6 mM Na2ATP, 1 mM DTT, 40.76 mM K-propionate, 14.5 mM 
creatine phosphate, 0.5 mM PMSF, 10 µM E64, 40 µM leupeptin, pH 7.1 and pCa 9 at 15 
°C). 
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For contractile measurements, single fibres or small fibre bundles [~0.07 mm2 cross sectional 
area (CSA) and ~ 0.5 mm length] were dissected in glycerinating solution at 4 °C. Fibre 
bundles were prepared if the fibre CSA was too small for reliable force measurements. 
Aluminium T-clips were attached to both ends of the preparation followed by chemical 
skinning in glycerinating solution containing 1 % TritonX-100 for 10 min (single fibres) or 
30 min (bundles) at 4 °C. The preparations were then stored at 4 °C in glycerinating solution 
until mounting onto a permeabilised fibre apparatus between a length motor and a force 
transducer (ASI 802D, ASI 403A, ASI 315C-I, respectively, Aurora Scientific Inc., Canada) 
in relaxing-solution. All force measurements were performed at sarcomere lengths of 2.5 µm 
[optimal myofilament overlap, (75)] and at a temperature of 20 °C (bath temperature 
controller ASI 825A, Aurora Scientific). The sarcomere length was set and the CSA was 
measured as described in (62). 
 
Prior to [Ca2+]-induced activations preparations were pre-activated for 1 min in 100 mM 
BES, 0.1mM EGTA, 6.42 mM MgCl2, 6 mM Na2ATP, 41.14 mM K-propionate, 14.5 mM 
creatine phosphate, 6.9 mM HDTA (pH 7.1 and pCa 9 at 15 °C). Maximal isometric 
contraction (Fmax) was measured by bathing fibres in saturating [Ca2+] buffer (100 mM BES, 
7 mM CaEGTA, 6.28 mM MgCl2, 6 mM Na2ATP, 40.64 mM K-propionate, 14.5 mM 
creatine phosphate, pH 7.1 and pCa 4.5 at 15 °C) until a force plateau was achieved. The 
maximal specific force (Fmax at pCa 4.5 normalised to the CSA) is presented in this study. 
Force/pCa curves and pCa 50 were measured as described in (20). The rate constant of 
tension re-development (Ktr) was measured by allowing the preparations to shorten to 70% of 
the initial length for 30 ms followed by re-stretch to 100 % and fitting the data to a mono-
exponential function using Labview (National Instruments, USA) as described in (20). Active 
stiffness was measured immediately after the Ktr protocol as described previously (32, 76). In 
brief, we measured the force response (F1) to six 2 s length changes (∆L: +0.3 %, +0.6 %, 
+0.9 %, -0.3 %, -0.6 %, -0.9 %; Supplementary Fig. 4). ∆L was plotted against the force 
changes (∆F) and a linear regression was fitted to obtain the slope using Graph Pad, Prism 
(Version 5.01). 
 
The MHC content of measured fibres was determined as described previously (62) and the 
proportion of each MHC was determined by densitometry. Single myofibres/fibre bundles 
containing exclusively slow MHC (>90 % type-1), exclusively fast MHC (>90 % type-2A or 
2X) or a mixture of both (11–90 % type-1 or type-2A/2X) were grouped for analysis. The 
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contractile properties of bundles and hybrid fibres containing a mix of type-1 and type-2A/2X 
MHC represent the average properties of both fibre types. The Ktr in bundles/hybrid fibres is 
highly variable due to the physiologically difference in type-1 or type-2A/2X fibres and was 
therefore not presented. Preparations were excluded from the analysis if the Fmax decreased 
>15 % during the protocol. Single myofibres from eight control biopsies (age 6-54 y) and 
bundles from two control biopsies (aged 0.6 and 6 y) were pooled for statistical analysis. 
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Figures: 
Fig. 1: Dominant mutations in TPM3 affect amino acids located within or close to actin 
binding domains 
Tropomyosins form α-helical coiled-coil dimers via a seven residue repeat motive in their 
amino acid sequence [a-b-c-d-e-f-g] as illustrated in (A-B). Positions a and d (blue) are 
usually hydrophobic and create a hydrophobic pocket between two tropomyosin chains 
facilitating dimerisation in a “knobs-into-holes” fashion. Positions g and e (green) are 
occupied by charged amino acids that further stabilise the dimer through inter-helical salt 
bridges. Positions b, c and f (yellow) localise to the surface of the TM dimer and likely 
modulate interactions with protein binding partners such as actin and troponin. (C) A ribbon 
model of a whole tropomyosin dimer with the actin binding domains marked in pink on one 
strand. The residues affected by dominant mutations in TPM3 are shown. All affected 
residues are located in or close to actin binding domains. Eight mutations affect residues in 
the b, c or f positions of the repeat (yellow). Three mutations affect residues in the a and d 
position (blue) and two affect residues in the g and e position (green). RCSB Protein Data 
Bank access code for protein structure model is 1C1G [tropomyosin dimer, Whitby and 
Phillips (23)]. Swiss-PDB Viewer v4.1.0 was used to create molecular graphics (66).  
 
Fig. 2: TPM3-myopathy patients have slow fibre hypotrophy and a deregulation of slow 
and fast muscle fibre proportions 
(A) ATPase pH 4.6 stained muscle cross section of one control and four patients with 
mutations at residue R168, of α-TPMslow demonstrating a selective hypotrophy of slow type-1 
myofibres. Fast type-2 fibres are between 1.7 and 5.2 times larger in size than type-1 fibres, 
whereas age-matched controls (age between 0.8 -57 y) showed roughly equally sized fibres 
(B). This corresponds to a fibre-size disproportion (FSD) between 41 % and 78.3 % (C). 
Patients with TPM3 mutations show an abnormal fibre type distribution ranging from 
complete type-1 fibre predominance (A: Patient 10) to type-2 fibre predominance (A: Patient 
8). (D) In the majority of control biopsies between 40-60 % of the CSA is composed of type-
1 fibres. TPM3-myopathy patients have either below 40 % or above 60 % type-1 fibre area. 
Fibre type measurements were performed twice at different times from the same biopsy in 
Patients 2, 3c, 6b and 8 (also see Supplementary Tab. 2) and the plotted values represent the 
average of both measurements. All images were taken at 100x magnification. Fibre size 
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measurements and further information on patient and control biopsies are summarised in 
Supplementary Tab. 2. 
 
Fig. 3: Tropomyosin isoform ratios are not commonly altered and mutant α-TPMslow is 
expressed in TPM3-myopathy patient muscle 
(Ai) A representative Western blot of TPM3-myopathy patient and control muscle tissue 
showing the three skeletal muscle tropomyosin isoforms (β-TPM, α-TMfast and α-TPMslow). In 
normal muscle, type-1 fibres contain about 50:50 α-TPMslow/β-TPM and type-2 fibres contain 
about 50:50 α-TPMfast/β-TPM. Most sample had β-TPM and α-TPMfast/slow levels consistent 
with the relative proportion of type-1 and type-2 fibres present in the sample (% type-1 fibre 
area was determined from ATPase staining, see Supplementary Tab. 2). Only one patient 
(TPM3 M9R mutation, lane 5) had reduced β-TPM levels and increased expression of α-
TPMslow relative to other tropomyosin isoforms and the fibre type proportion in the biopsy as 
described previously (25). (Aii-iiii) Densitometry analysis of Western blots from 10 patients 
with mutations L100M (n=3), R168C (n=1), R168G (n=1), R168H (n=3), K169E (n=1), 
R245G (n=1) was performed to quantify the proportion of each tropomyosin isoform as a 
percentage of total TPM. The relative abundance of each isoform was plotted against the % 
type-1 fibre area (measurements from TPM3 M9R patient are not included). (Aii) β-TPM 
levels are about 50 % of total tropomyosin in patients and controls. (Aiii-iiii) About 50 % of 
tropomyosin is α-TPMfast/slow, but the amount of these fibre-type specific isoforms correlates 
closely with the % type-1 fibre area in both patients and controls (positive correlation for α-
TPMslow, negative correlation for α-TPMfast). Linear regression analysis showed that slopes of 
patient and controls were not significantly different for any of the three isoforms (p=0.4997, 
0.9538 and 0.4595 for α-TPMslow, α-TPMfast and β-TPM, respectively). (B) Isoelectric 
focusing of patient and control muscle lysates shows three spots (corresponding to β-TPM, α-
TPMfast, α-TPMslow). An additional spot (marked by an arrow) consistent with the predicted 
isoelectric point (pI) of each mutation (as annotated, wild-type α-TPMslow is 4.69) is present 
in patient biopsies. Mutant α-TPMslow accounted for 27-45% of total α-TPMslow in different 
patient biopsies (annotated in the blot, the proportion of each tropomyosin in patient slow 
fibres is given in Supplementary Tab. 3). Note the ratio of expression of α-TPMfast/slow 
depends on the percentage of slow and fast myofibres in the biopsy (e.g. Patient 8 (R168C) 
mainly contains fast myofibres). Picture 3 from the left in (B) is reprinted from Neuromuscul 
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Disord, 20/7 Waddell et al., Evidence for a dominant negative disease mechanism in cap 
myopathy due to TPM3, 464-466, Copyright (2010), with permission from Elsevier. 
 
Fig. 4: Mutant α-TPMslow R168C proteins has a reduced affinity to filamentous actin 
Phalloidin stabilised actin filaments were co-sedimented with incremental amounts of 
tropomyosin and the pelleted fractions were analysed by SDS-PAGE. (A) A representative 
SDS-PAGE of wild-type α-TPMslow protein as was used for densitometry analysis. (B) The 
ratio of TPM/actin was plotted vs. total [TPM] added and a Hill’s equation was fitted. The Kd 
was increased in α-TPMslow R168C compared to α-TPMslow wild-type and K169E suggesting 
weaker binding affinity to actin (771.4±188.6 nM, 180.2±37.6 nM, 164.0±110.6 nM for α-
TPMslow R168C, wild-type and K169E, respectively). The Hill’s coefficient h and maximal 
binding (Bmax) was similar in all three proteins (h = wild-type 4.471±3.0, R168C 3.308±2.4, 
K169E 1.602±1.3; Bmax wild-type 0.489±0.055, R168C 0.431±0.078 and K169E 
0.443±0.156). Values are best-fit values ± 95% confidence interval. 
 
Fig. 5: TPM3 patients show increased phosphorylation of tropomyosin and ectopic 
expression of fast fibre specific α-actinin-3 in slow myofibres 
(A) Consecutive sections were labelled with type-1 and type-2a MHC (blue and green, co-
labelled respectively), type-2 MHC (red), α-actinin-3 (green) and troponin-Tfast (green) (the 
same fibre in multiple stains is indicated by a white arrow). Troponin-Tfast is only expressed 
in fast fibres as expected. Abnormal expression of α-actinin-3, a fast fibre specific Z-disc 
protein, was observed in type-1 myofibres of Patients 10, 4 and 6a (yellow stars). The biopsy 
of Patient 6b showed similar abnormalities but is not shown in this panel. Other patients had 
normal expression of α-actinin-3. Staining of Patient 1 and 8 are representative for these 
patients. (Bi) S283 is conserved and can be phosphorylated in all three sarcomeric 
tropomyosin proteins. (Bii) We assessed the level of S283 phosphorylation (pTPM) and total 
tropomyosin protein levels by duplicate Western blot and equal loading was confirmed by 
using sarcomeric actin (s Actin) (representative Western blot shown). The phosphorylation 
status of all three tropomyosin isoforms was determined by densitometry and normalised to 
the total tropomyosin levels. The graph shows phosphorylation levels normalised to the 
control average in (Biii) TPM3 patients and (Biiii) patients with congenital myopathies and 
muscular dystrophies due to mutations in TPM3, TPM2, ACTA1, DNM2, DMD and DYSF. 
Horizontal lines and error bars represent mean and standard deviation. Phosphorylation was 
commonly increased in both TPM3 patients and patients with other genetic causes of muscle 
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disease. Statistical analysis was only performed on patients with the R168H mutation due to 
insufficient data points for other groups. Phosphorylation was significantly higher in patients 
with the R168H mutation compared to controls (*p<0.05, Mann-Whitney U test).  
 
Fig. 6: The force generation at saturating [Ca
2+
] is decreased in TPM3-myopathy 
patients 
Maximal force generation (Fmax) measured at pCa 4.5 and sarcomere length of 2.5 µm, 
normalised to fibre CSA. (A) A typical force trace from a patient (Patient 6) and control type-
1 fibre. Most TPM3 patients showed a significant force deficit in type-1 myofibres (C) 
whereas type-2 fibres produced similar maximal force compared to controls (B). In hybrid 
fibres and fibre bundles all patients had a slightly lower force average, however only Patient 
1 showed a significant force deficit (D). Cslow = Control type-1 fibres (pooled from eight 
biopsies aged: 11-54 y), Cfast = Control type-2 fibres (pooled from eight biopsies aged: 6-54 
y), Ch/b= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 11-54 y) and 
small fibre bundles (bundles were taken from two biopsies of 0.9 y and 6 y old controls). P = 
Patient. The black line in (B-D) indicates the average. *** p<0.0001, * p<0.01, one-way 
ANOVA. 
 
Fig. 7: The force deficit in TPM3-myopathy patients is likely due to abnormal cross-
bridge cycling 
We assessed the rate of tension re-development (Ktr) (A)) and active stiffness (B) in TPM3-
myopathy patients to investigate if the force deficit in patient type-1 fibres was due to altered 
cross-bridge cycling. A typical Ktr trace of a patient (Patient 6) and a control are shown in 
(Ai). The Ktr in single myofibres from TPM3 patient biopsies and control biopsies are shown 
in (Aii) (type-1) and (Aiii) (type-2). Note that due to different MHC-ATPase properties the 
Ktr is physiologically higher in type-2 than in type-1 fibres. (Aii) The type-1 fibres of most 
TPM3 patients showed a significant decrease in Ktr compared to control type-1 fibres 
(exceptions: Patient 1, 2 and 3a (*** p<0.0001, * p<0.01, one-way ANOVA) (Aiii) The type-
2 fibres were not different to control type-2 fibres, with the exception of Patient 6 which 
showed a small decrease in Ktr. (B) Active stiffness was analysed by plotting the length 
changes (∆L) against the force changes (∆F) and fitting a linear regression to the data. A 
representative graph of type-1 fibres from Patient 4 and from controls is shown in (Bi: 
absolute length change) and (Bii: length change/Fmax). Graphs from other all other samples 
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are presented in Supplementary Fig. 6. Error bars represent standard deviation. (Biii-v) The 
slope of the linear regression was not significantly different from controls in all fibre-types in 
most patients with the exception of type-1 fibres or bundles/hybrid fibres of Patient 1, 2 and 7 
where stiffness was reduced (*p<0.01 ,**p<0.001 ,*** p <0.0001, one-way ANOVA). 
However, a trend towards a small reduction was present in type-1 fibres and bundles/hybrid 
fibres of most patients (Biii-iiii). (vi-vii) When ∆F was normalised to Fmax the slope was not 
significantly different from controls with the exception of P3c, which showed an increase in 
the slope (I, *** p <0.0001, one-way ANOVA). Error bars represent standard deviation. Cslow 
and Cfast = Control type-1 and type-2 fibres (pooled from eight biopsies aged: 11 - 54 y), Ch/b 
= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 6 - 54 y) and small 
fibre bundles (bundles were taken from two biopsies of 0.9 y and 6 y old controls). The black 
line in all scatter plots indicates the average. 
 
Fig. 8: Ca
2+
-sensitivity is decreased in TPM3-myopathy patients resulting in reduced 
specific force generation at physiological [Ca
2+
] 
(A) Specific force generation at incremental [Ca2+] in skinned type-1 fibres (i), hybrid fibres 
or bundles (ii) and type-2 fibres (C) shown as percent of Fmax fitted to a variable slope log 
(dose) response curve. Note the rightward shift of the force/pCa curve in type-1 fibres, hybrid 
fibres/bundles in TPM3 patients, whereas type-2 fibres were not different to controls. The 
dotted lines indicate the pCa50 ([Ca2+] required to achieve 50 % of maximal force) and the 
yellow area indicates physiological cytoplasmic [Ca2+] during muscle contraction (between 1 
- 5 µM) (B) The pCa 50 was significantly higher in type-1 fibres, hybrid fibres/ bundles of 
TPM3 patients compared to controls and type-2 fibres of TPM3 patients. (C) Specific force 
generation measured at pCa 6.0 (1 µM, physiological calcium). The force was significantly 
lower in (i) type-1 fibres and (ii) hybrid fibres/bundles of all TPM3 patients, but was not 
different from controls in (iii) type-2 fibres. Cslow and Cfast = Control type-1 and type-2 fibres 
(pooled from eight biopsies aged: 11-54 y), Ch/b = Control hybrid fibres (contain a mix of 
type-1 and type-2 MHC, age 6-54 y) and small fibre bundles (bundles were taken from two 
biopsies of 0.9 y and 6 y old controls). The black line in the scatter plot indicates the average 
and error bars in force/pCa curves are standard deviations. *** p<0.0001, * p<0.01, one-way 
ANOVA. P=Patient, C= control. 
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Table 1: Patient cohort with dominant TPM3 mutations 
P Mutation 
in TPM3 
Disease Muscle 
type 
Sex Age at 
biopsy 
Clinical 
classification 
Publication Contractile 
studies 
1 K169E CFTD Q M 16 m moderate (1): P 2 Y 
2 R245G CFTD Q M 20 m moderate (1): P 1 Y 
3a L100M CFTD Q F 3 y mild (1): P 5 Y 
3b L100M CFTD B M 30 y mild (1): P 7 Y 
3c L100M CFTD B M 36 y mild (1): P 8 Y 
4 R168G CFTD Q M 10 y mild (1): P 3 Y 
5 R168H  CFTD Q F 40 y mild unpublished Y 
6a R168H NM D F 20 y mild (1): P 10 N 
6b R168H  CFTD ? M 56 y mild (1): P 11 Y 
7 R168C Cap ? M 3 y mild (14): P 1 Y 
8 R168C CFTD Q F 19 y moderate (1): P 9 Y 
9 M9R NM Q F 21 y mild (8); (37): P 1 N 
10 R168H NM D M 53 y mild (13): P III-4 N 
11 E241K CFTD Q F 0.5y moderate (2): P 311-1 N 
12 R91P CFTD Q F 0.5y severe (2): P 913-1 N 
Q=Quadriceps, B = Biceps, D = Deltoid, P = Patient 
 
Abbreviations 
α-tropomyosinslow      α-TPMslow 
α-tropomyosinfast      α-TPMfast 
bovine serum albumin     BSA 
β-tropomyosin       β-TPM 
congenital fibre-type disproportion    CFTD 
cross sectional area      CSA 
immunohistochemistry     IHC 
−log of molar free [Ca2+]     pCa 
maximal isometric contraction     Fmax 
myosin heavy chain      MHC 
percentage fibre-size disproportion     % FSD 
phosphate buffered saline      PBS 
two-dimensional SDS polyacrylamide gel electrophoresis 2D-SDS-PAGE 
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Fig. 1: Dominant mutations in TPM3 affect amino acids located within or close to actin binding domains  
Tropomyosins form α-helical coiled-coil dimers via a seven residue repeat motive in their amino acid 
sequence [a-b-c-d-e-f-g] as illustrated in (A-B). Positions a and d (blue) are usually hydrophobic and create 
a hydrophobic pocket between two tropomyosin chains facilitating dimerisation in a “knobs-into-holes” 
fashion. Positions g and e (green) are occupied by charged amino acids that further stabilise the dimer 
through inter-helical salt bridges. Positions b, c and f (yellow) localise to the surface of the TM dimer and 
likely modulate interactions with protein binding partners such as actin and troponin. (C) A ribbon model of 
a whole tropomyosin dimer with the actin binding domains marked in pink on one strand. The residues 
affected by dominant mutations in TPM3 are shown. All affected residues are located in or close to actin 
binding domains. Eight mutations affect residues in the b, c or f positions of the repeat (yellow). Three 
mutations affect residues in the a and d position (blue) and two affect residues in the g and e position 
(green). RCSB Protein Data Bank access code for protein structure model is 1C1G [tropomyosin dimer, 
Whitby and Phillips (23)]. Swiss-PDB Viewer v4.1.0 was used to create molecular graphics (66).  
177x107mm (300 x 300 DPI)  
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Fig. 2: TPM3-myopathy patients have slow fibre hypotrophy and a deregulation of slow and fast muscle fibre 
proportions  
(A) ATPase pH 4.6 stained muscle cross section of one control and four patients with mutations at residue 
R168, of α-TPMslow demonstrating a selective hypotrophy of slow type-1 myofibres. Fast type-2 fibres are 
between 1.7 and 5.2 times larger in size than type-1 fibres, whereas age-matched controls (age between 
0.8 -57 y) showed roughly equally sized fibres (B). This corresponds to a fibre-size disproportion (FSD) 
between 41 % and 78.3 % (C). Patients with TPM3 mutations show an abnormal fibre type distribution 
ranging from complete type-1 fibre predominance (A: Patient 10) to type-2 fibre predominance (A: Patient 
8). (D) In the majority of control biopsies between 40-60 % of the CSA is composed of type-1 fibres. TPM3-
myopathy patients have either below 40 % or above 60 % type-1 fibre area. Fibre type measurements were 
performed twice at different times from the same biopsy in Patients 2, 3c, 6b and 8 (also see 
Supplementary Tab. 2) and the plotted values represent the average of both measurements. All images 
were taken at 100x magnification. Fibre size measurements and further information on patient and control 
biopsies are summarised in Supplementary Tab. 2.  
177x106mm (300 x 300 DPI)  
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Fig. 3: Tropomyosin isoform ratios are not commonly altered and mutant α-TPMslow is expressed in TPM3-
myopathy patient muscle  
(Ai) A representative Western blot of TPM3-myopathy patient and control muscle tissue showing the three 
skeletal muscle tropomyosin isoforms (β-TPM, α-TMfast and α-TPMslow). In normal muscle, type-1 fibres 
contain about 50:50 α-TPMslow/β-TPM and type-2 fibres contain about 50:50 α-TPMfast/β-TPM. Most 
sample had β-TPM and α-TPMfast/slow levels consistent with the relative proportion of type-1 and type-2 
fibres present in the sample (% type-1 fibre area was determined from ATPase staining, see Supplementary 
Tab. 2). Only one patient (TPM3 M9R mutation, lane 5) had reduced β-TPM levels and increased expression 
of α-TPMslow relative to other tropomyosin isoforms and the fibre type proportion in the biopsy as described 
previously (25). (Aii-iiii) Densitometry analysis of Western blots from 10 patients with mutations L100M 
(n=3), R168C (n=1), R168G (n=1), R168H (n=3), K169E (n=1), R245G (n=1) was performed to quantify 
the proportion of each tropomyosin isoform as a percentage of total TPM. The relative abundance of each 
isoform was plotted against the % type-1 fibre area (measurements from TPM3 M9R patient are not 
included). (Aii) β-TPM levels are about 50 % of total tropomyosin in patients and controls. (Aiii-iiii) About 50 
% of tropomyosin is α-TPMfast/slow, but the amount of these fibre-type specific isoforms correlates closely 
with the % type-1 fibre area in both patients and controls (positive correlation for α-TPMslow, negative 
correlation for α-TPMfast). Linear regression analysis showed that slopes of patient and controls were not 
significantly different for any of the three isoforms (p=0.4997, 0.9538 and 0.4595 for α-TPMslow, α-TPMfast 
and β-TPM, respectively). (B) Isoelectric focusing of patient and control muscle lysates shows three spots 
(corresponding to β-TPM, α-TPMfast, α-TPMslow). An additional spot (marked by an arrow) consistent with 
the predicted isoelectric point (pI) of each mutation (as annotated, wild-type α-TPMslow is 4.69) is present 
in patient biopsies. Mutant α-TPMslow accounted for 27-45% of total α-TPMslow in different patient biopsies 
(annotated in the blot, the proportion of each tropomyosin in patient slow fibres is given in Supplementary 
Tab. 3). Note the ratio of expression of α-TPMfast/slow depends on the percentage of slow and fast 
myofibres in the biopsy (e.g. Patient 8 (R168C) mainly contains fast myofibres). Picture 3 from the left in 
(B) is reprinted from Neuromuscul Disord, 20/7 Waddell et al., Evidence for a dominant negative disease 
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Fig. 4: Mutant α-TPMslow R168C proteins has a reduced affinity to filamentous actin  
Phalloidin stabilised actin filaments were co-sedimented with incremental amounts of tropomyosin and the 
pelleted fractions were analysed by SDS-PAGE. (A) A representative SDS-PAGE of wild-type α-TPMslow 
protein as was used for densitometry analysis. (B) The ratio of TPM/actin was plotted vs. total [TPM] added 
and a Hill’s equation was fitted. The Kd was increased in α-TPMslow R168C compared to α-TPMslow wild-
type and K169E suggesting weaker binding affinity to actin (771.4±188.6 nM, 180.2±37.6 nM, 164.0±110.6 
nM for α-TPMslow R168C, wild-type and K169E, respectively). The Hill’s coefficient h and maximal binding 
(Bmax) was similar in all three proteins (h = wild-type 4.471±3.0, R168C 3.308±2.4, K169E 1.602±1.3; 
Bmax wild-type 0.489±0.055, R168C 0.431±0.078 and K169E 0.443±0.156). Values are best-fit values ± 
95% confidence interval.  
90x87mm (300 x 300 DPI)  
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Fig. 5: TPM3 patients show increased phosphorylation of tropomyosin and ectopic expression of fast fibre 
specific α-actinin-3 in slow myofibres  
(A) Consecutive sections were labelled with type-1 and type-2a MHC (blue and green, co-labelled 
respectively), type-2 MHC (red), α-actinin-3 (green) and troponin-Tfast (green) (the same fibre in multiple 
stains is indicated by a white arrow). Troponin-Tfast is only expressed in fast fibres as expected. Abnormal 
expression of α-actinin-3, a fast fibre specific Z-disc protein, was observed in type-1 myofibres of Patients 
10, 4 and 6a (yellow stars). The biopsy of Patient 6b showed similar abnormalities but is not shown in this 
panel. Other patients had normal expression of α-actinin-3. Staining of Patient 1 and 8 are representative 
for these patients. (Bi) S283 is conserved and can be phosphorylated in all three sarcomeric tropomyosin 
proteins. (Bii) We assessed the level of S283 phosphorylation (pTPM) and total tropomyosin protein levels 
by duplicate Western blot and equal loading was confirmed by using sarcomeric actin (s Actin) 
(representative Western blot shown). The phosphorylation status of all three tropomyosin isoforms was 
determined by densitometry and normalised to the total tropomyosin levels. The graph shows 
phosphorylation levels normalised to the control average in (Biii) TPM3 patients and (Biiii) patients with 
congenital myopathies and muscular dystrophies due to mutations in TPM3, TPM2, ACTA1, DNM2, DMD and 
DYSF. Horizontal lines and error bars represent mean and standard deviation. Phosphorylation was 
commonly increased in both TPM3 patients and patients with other genetic causes of muscle disease. 
Statistical analysis was only performed on patients with the R168H mutation due to insufficient data points 
for other groups. Phosphorylation was significantly higher in patients with the R168H mutation compared to 
controls (*p<0.05, Mann-Whitney U test).  
192x180mm (300 x 300 DPI)  
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Fig. 6: The force generation at saturating [Ca2+] is decreased in TPM3-myopathy patients  
Maximal force generation (Fmax) measured at pCa 4.5 and sarcomere length of 2.5 µm, normalised to fibre 
CSA. (A) A typical force trace from a patient (Patient 6) and control type-1 fibre. Most TPM3 patients showed 
a significant force deficit in type-1 myofibres (C) whereas type-2 fibres produced similar maximal force 
compared to controls (B). In hybrid fibres and fibre bundles all patients had a slightly lower force average, 
however only Patient 1 showed a significant force deficit (D). Cslow = Control type-1 fibres (pooled from 
eight biopsies aged: 11-54 y), Cfast = Control type-2 fibres (pooled from eight biopsies aged: 6-54 y), 
Ch/b= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 11-54 y) and small fibre bundles 
(bundles were taken from two biopsies of 0.9 y and 6 y old controls). P = Patient. The black line in (B-D) 
indicates the average. *** p<0.0001, * p<0.01, one-way ANOVA.  
172x118mm (300 x 300 DPI)  
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Fig. 7: The force deficit in TPM3-myopathy patients is likely due to abnormal cross-bridge cycling  
We assessed the rate of tension re-development (Ktr) (A)) and active stiffness (B) in TPM3-myopathy 
patients to investigate if the force deficit in patient type-1 fibres was due to altered cross-bridge cycling. A 
typical Ktr trace of a patient (Patient 6) and a control are shown in (Ai). The Ktr in single myofibres from 
TPM3 patient biopsies and control biopsies are shown in (Aii) (type-1) and (Aiii) (type-2). Note that due to 
different MHC-ATPase properties the Ktr is physiologically higher in type-2 than in type-1 fibres. (Aii) The 
type-1 fibres of most TPM3 patients showed a significant decrease in Ktr compared to control type-1 fibres 
(exceptions: Patient 1, 2 and 3a (*** p<0.0001, * p<0.01, one-way ANOVA) (Aiii) The type-2 fibres were 
not different to control type-2 fibres, with the exception of Patient 6 which showed a small decrease in Ktr. 
(B) Active stiffness was analysed by plotting the length changes (∆L) against the force changes (∆F) and 
fitting a linear regression to the data. A representative graph of type-1 fibres from Patient 4 and from 
controls is shown in (Bi: absolute length change) and (Bii: length change/Fmax). Graphs from other all other 
samples are presented in Supplementary Fig. 6. Error bars represent standard deviation. (Biii-v) The slope 
of the linear regression was not significantly different from controls in all fibre-types in most patients with 
the exception of type-1 fibres or bundles/hybrid fibres of Patient 1, 2 and 7 where stiffness was reduced 
(*p<0.01 ,**p<0.001 ,*** p <0.0001, one-way ANOVA). However, a trend towards a small reduction was 
present in type-1 fibres and bundles/hybrid fibres of most patients (Biii-iiii). (vi-vii) When ∆F was normalised 
to Fmax the slope was not significantly different from controls with the exception of P3c, which showed an 
increase in the slope (I, *** p <0.0001, one-way ANOVA). Error bars represent standard deviation. Cslow 
and Cfast = Control type-1 and type-2 fibres (pooled from eight biopsies aged: 11 - 54 y), Ch/b = Control 
hybrid fibres (contain a mix of type-1 and type-2 MHC, age 6 - 54 y) and small fibre bundles (bundles were 
taken from two biopsies of 0.9 y and 6 y old controls). The black line in all scatter plots indicates the 
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Fig. 8: Ca2+-sensitivity is decreased in TPM3-myopathy patients resulting in reduced specific force 
generation at physiological [Ca2+]  
(A) Specific force generation at incremental [Ca2+] in skinned type-1 fibres (i), hybrid fibres or bundles (ii) 
and type-2 fibres (C) shown as percent of Fmax fitted to a variable slope log (dose) response curve. Note 
the rightward shift of the force/pCa curve in type-1 fibres, hybrid fibres/bundles in TPM3 patients, whereas 
type-2 fibres were not different to controls. The dotted lines indicate the pCa50 ([Ca2+] required to achieve 
50 % of maximal force) and the yellow area indicates physiological cytoplasmic [Ca2+] during muscle 
contraction (between 1 - 5 µM) (B) The pCa 50 was significantly higher in type-1 fibres, hybrid fibres/ 
bundles of TPM3 patients compared to controls and type-2 fibres of TPM3 patients. (C) Specific force 
generation measured at pCa 6.0 (1 µM, physiological calcium). The force was significantly lower in (i) type-1 
fibres and (ii) hybrid fibres/bundles of all TPM3 patients, but was not different from controls in (iii) type-2 
fibres. Cslow and Cfast = Control type-1 and type-2 fibres (pooled from eight biopsies aged: 11-54 y), Ch/b 
= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 6-54 y) and small fibre bundles 
(bundles were taken from two biopsies of 0.9 y and 6 y old controls). The black line in the scatter plot 
indicates the average and error bars in force/pCa curves are standard deviations. *** p<0.0001, * p<0.01, 
one-way ANOVA. P=Patient, C= control.  
180x165mm (300 x 300 DPI)  
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Abstract 
Dominant mutations in TPM3, encoding α-tropomyosinslow, cause a congenital myopathy 
characterised by generalised muscle weakness. Here, we used a multidisciplinary approach to 
investigate the mechanism of muscle dysfunction in twelve TPM3-myopathy patients. 
We confirm that slow myofibre hypotrophy is a diagnostic hallmark of TPM3-myopathy, and 
is commonly accompanied by skewing of fibre-type ratios (either slow or fast fibre 
predominance). Patient muscle contained normal ratios of the three tropomyosin isoforms and 
normal fibre-type expression of myosins and troponins. Using 2D-PAGE, we demonstrate 
that mutant α-tropomyosinslow was expressed, suggesting muscle dysfunction is due to a 
dominant-negative effect of mutant protein on muscle contraction. Molecular modelling 
suggested mutant α-tropomyosinslow likely impacts actin-tropomyosin interactions and, 
indeed, co-sedimentation assays showed reduced binding of mutant α-tropomyosinslow 
(R168C) to filamentous actin. 
Single fibre contractility studies of patient myofibres revealed marked slow myofibre specific 
abnormalities. At saturating [Ca2+] (pCa 4.5), patient slow fibres produced only 63% of the 
contractile force produced in control slow fibres and had reduced acto-myosin cross-bridge 
cycling kinetics. Importantly, due to reduced Ca2+-sensitivity, at sub-saturating [Ca2+] (pCa 6, 
levels typically released during in vivo contraction) patient slow fibres produced only 26% of 
the force generated by control slow fibres.  
Thus, weakness in TPM3-myopathy patients can be directly attributed to reduced slow fibre 
force at physiological [Ca2+], and impaired acto-myosin cross-bridge cycling kinetics. Fast 
myofibres are spared; however, they appear to be unable to compensate for slow fibre 
dysfunction. Abnormal Ca2+-sensitivity in TPM3-myopathy patients suggests Ca2+-sensitising 
drugs may represent a useful treatment for this condition.  
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Introduction 
Dominant mutations in the TPM3 gene, encoding α-tropomyosinslow (α-TPMslow), cause a 
congenital myopathy characterised by mild to moderate early onset, non-progressive 
generalised muscle weakness (1-3). Axial and respiratory muscles are commonly involved 
and many patients require night-time ventilatory support (1, 2). Recessive mutations, causing 
loss of protein, are rare with only four instances reported to date in patients with relatively 
severe clinical presentations (4-7). In contrast, more than 40 families with dominant TPM3 
missense mutations have been identified involving 19 different residues (1, 3, 7-13), 
Supplementary Tab. 1). Histologically, many TPM3 patients present with slow skeletal 
myofibre hypotrophy in the absence of additional pathological features, resulting in a clinical 
diagnosis of congenital fibre-type disproportion (CFTD) (3). Some patients also exhibit 
nemaline bodies or cores in myofibres and are classified as nemaline myopathy (8) or core 
myopathy (1, 11, 14), respectively. The same mutation in TPM3 can cause a variety of 
histological phenotypes (Supplementary Tab. 1) (1, 3, 7, 14).  
Three tropomyosin isoforms are present in the skeletal muscle sarcomere (15). TPM1 and 
TPM3 encode the two α-tropomyosins expressed exclusively in fast fibres (TPM1; α-TPMfast, 
Tpm1.st) or slow fibres (TPM3; α-TPMslow, Tpm3.12st), respectively. TPM2 encodes β-
tropomyosin (β-TPM, Tpm2.2st) and is expressed in both fibre types (15-17). Tropomyosin 
forms alpha-helical coiled-coil heterodimers between one α- and one β-chain. These dimers 
polymerise head-to-tail into a continuous filament that associates along the entire length of 
the actin thin filament and interacts with the troponin complex to regulate Ca2+-mediated 
actin-myosin cross-bridge cycling during muscle contraction. The structure of tropomyosin is 
conferred by a seven residue repeat motive [a-b-c-d-e-f-g] (Fig. 1A and B) (18). Residues at 
positions a and d in the repeat are typically hydrophobic, creating a hydrophobic pocket 
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between two tropomyosin chains facilitating dimerisation (blue). Charged residues at 
positions g and e (green) stabilise the dimer through inter-helical salt bridges. Positions b, c 
and f (yellow) localise to the surface of tropomyosin dimers and likely modulate interactions 
with proteins such as actin and troponin.  
 
Many dominant TPM3 mutations (11/19) affect positions b, c or f on the outer surface of the 
dimer (Fig. 1C, yellow). Only five mutations affect positions a and d in the hydrophobic 
pocket (Fig. 1C, blue) and three mutations affect positions g and e constituting the inter-
helical salt bridges (Fig. 1C, green). All mutations fall within, or very close to, one of the 
seven actin binding regions of tropomyosin (Fig. 1C, purple shaded area of the molecule) 
(19). In particular, there is a striking concentration of mutations within the fifth actin-binding 
region of α-TPMslow (R168H, R168G, R168C, K169E, E174A) some of which are recurrent 
in several unrelated families (e.g. R168 residue is mutated in 20 different families). 
Although the structure and function of tropomyosin is well established, the mechanism(s) by 
which mutations in TPM3 cause muscle weakness remains poorly understood. Two recent 
studies showed that four patients with dominant TPM3 mutations had abnormal cross-bridge 
cycling kinetics and Ca2+-sensitivity of contraction in single skeletal myofibres isolated from 
patient biopsies [n=3 (20), n=1 (21)]. However, these studies were limited by small sample 
sizes, and separate assessment of the properties of slow versus fast myofibres was only 
possible to a limited extend. In this study, we aimed to unravel the mechanism of muscle 
weakness in a cohort of 12 patients with dominant TPM3 mutations. We performed thorough 
histological characterisation, assessed thin filament protein expression and quantified the 
contractile properties of single myofibres isolated from patient muscle specimens (10/12 
patients, Tab. 1). 
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Results 
TPM3-myopathy patients have slow fibre hypotrophy and deregulation of slow and 
fast muscle fibre proportions 
The main histological characteristic in all patients with TPM3 mutations is selective 
hypotrophy of slow-twitch type-1 fibres, compared to fast-twitch type-2 fibres (1, 3, 7) (Fig. 
2A, ATPase pH 4.6, slow myofibres appear dark; see Supplementary Tab. 2 for 
measurements). On average, fast fibres were between 1.7 and 5.2 times larger in diameter 
than slow fibres (Fig. 2B), corresponding to a %FSD of 41 % - 78.3 % (Fig. 2C). The 
selective hypotrophy of slow fibres in TPM3 patients is consistent with the slow-fibre 
specific expression of α-TPMslow. 
Additionally, fibre-typing was skewed in patient biopsies, either towards fast fibre 
predominance (five patients, less than 30 % slow fibre area) or slow fibre predominance (six 
patients, more than 60 % slow fibre area), compared to age-matched control biopsies where 
the CSA occupied by either fibre-type is approximately 50:50 [this study and (22, 23)] (Fig. 
2D). Only one patient biopsy showed normal slow-fast fibre distribution (between 40-60 % 
slow fibre area). 
 
Tropomyosin isoform ratios are not commonly altered in TPM3-myopathy patients  
In normal muscle, the ratio of α/β tropomyosin molecules is approximately 50:50 β-TPM/α-
TPMfast in fast fibres and 50:50 β-TPM/α-TPMslow in slow fibres (24). A patient and 
transgenic mouse model carrying the TPM3 M9R mutation, the first mutation associated with 
nemaline myopathy, showed an imbalance of this ratio, with a dramatic excess of α-TPMslow 
relative to β-TPM in skeletal muscle (25) (Fig. 3Ai, Lane 5). This disruption in tropomyosin 
stoichiometry was proposed as a potential mechanism of muscle weakness (25). In contrast, 
in this cohort of 12 TPM3-myopathy patients, we observed normal ratios of α/β tropomyosin, 
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similar to controls (Fig. 3Ai). The scatter plots in Fig. 3Aii-iiii show the relative levels of 
each tropomyosin isoform relative to the type-1 fibre CSA, as determined by ATPase 
staining. β-TPM is present at equal amounts in slow and fast myofibres in all samples (~50 % 
of total tropomyosin, Fig. 3Aii). The relative expression of α-TPMslow and α-TPMfast 
correlates well with type-1 fibre CSA (positive correlation for α-TPMslow and negative 
correlation for α-TPMfast, Fig. 3Aiii and 3Aiiii). The linear regression slope fitted to the data 
was not significantly different between patients and controls, demonstrating a normal ratio of 
α/β tropomyosin isoforms in fast and slow fibres. 
 
Mutant α-TPMslow is expressed in muscle of TPM3-myopathy patients 
The autosomal dominant inheritance of TPM3 mutations within our cohort is consistent with 
the hypothesis that mutant α-TPMslow is expressed in slow skeletal myofibres and causes 
disease via a dominant-negative effect on thin filament function. To confirm mutant α-
TPMslow is present in patient muscle, we isolated the filamentous fractions (representing 
proteins incorporated in high-molecular weight structures such as sarcomeres) and performed 
2D-SDS-PAGE. Five patients in our cohort from whom skeletal muscle samples were 
available, had a mutation that resulted in an amino-acid substitutions affecting a charged 
residue leading to a predicted alteration in the isoelectric point (pI) of α-TPMslow. Thus, 
isoelectric focusing allowed us to separate the mutant from the wild-type protein on the basis 
of charge in these patients, and the second dimension urea-SDS gel separated the three 
tropomyosin isoforms from each other. The mutant α-TPMslow protein could then be observed 
as a left-sided (Fig. 3B; R186G, R91P, K169E, R168C) or right-sided shift (Fig. 3B, E241K) 
from the wild-type α-TPMslow and was present in all patient muscles. The total pool of α-
TPMslow (both wild-type and mutant isoforms) correlated with the slow fibre CSA (% type-1 
fibre area annotated above each blot, see Supplementary Tab. 2 for measurements). However, 
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mutant α-TPMslow was less abundant compared to wild-type, ranging from 27 to 45 % of total 
α-TPMslow (% mutant α-TPMslow annotated on each blot).  
 
The actin-binding properties of K169E and R168C mutant α-TPMslow proteins are 
altered 
The position of many TPM3 mutations within or close to actin binding sites suggest most 
mutations may influence interactions between α-TPMslow and actin filaments. Therefore, we 
performed actin-tropomyosin co-sedimentation assays with two recombinant mutant α-
TPMslow proteins (R168C and K169E) and compared their actin binding properties to wild-
type α-TPMslow. These mutations were chosen because they are both located in the fifth actin 
binding domain, the area that harbours a hotspot for myopathy causing mutations, and affect 
amino acids predicted to be involved in actin interactions. We co-sedimented incremental 
amounts of each of the three α-TPMslow proteins with 100 nM filamentous skeletal actin. Fig. 
4A shows a representative SDS-PAGE of the filamentous fraction isolated following 
ultracentrifugation, demonstrating dose-dependent binding of wild-type α-TPMslow to actin 
filaments. Densitometry data of the bound fraction versus the total amount of α-TPMslow 
added to the reaction was fitted to a Hill equation, to determine the binding constant Kd and 
the Hill coefficient (h) for all three α-TPMslow proteins (Fig. 4B). The α-TPMslow R168C 
protein showed reduced actin binding affinity compared to wild-type or the α-TPMslow K169E 
protein (Kd = 771.4±188.6 nM for R168C, 180.2±37.6 nM for wild-type and 164.0±110.6 nM 
for K169E, range represents 95% confidence interval). The Hill coefficient was similar in all 
three mutations (h = wild-type 4.471±3.0, R168C 3.308±2.4, K169E 1.602±1.3). These 
results suggest actin binding may be the mechanism by which the TPM3 R168C mutation 
alters contractile function and causes muscle weakness. 
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Fast fibre specific α-actinin-3 is ectopically expressed in slow fibres of patients with 
R168H/G TPM3 mutations 
As many TPM3 patient biopsies displayed a skewing to either slow- or fast- fibre 
predominance by ATPase stain, we stained serial muscle sections with antibodies recognizing 
fibre-type specific isoforms of MHC, troponin and α-actinin to investigate whether the 
expression of several fibre-type-specific proteins was normal (Fig. 5A, Supplementary Fig. 
1). Three patients (Patients 4, 6a and 6b, each with R168 substitutions), showed elevated 
levels of hybrid fibres expressing both slow and fast myosin isoforms. All other patients 
showed normal fibre profiling of myosin and troponin. Curiously, when further 
characterizing the expression profile of hybrid fibres in Patients 4, 6a, 6b and 10, we 
observed ectopic expression of α-actinin-3 in dedicated slow fibres as determined by the 
expression of myosin and troponin (Fig. 5A, Supplementary Fig. 1). α-Actinin-3 is a 
component of the Z-disc normally present in fast myofibres and has been found to be 
important for muscle performance (strength and speed) (26, 27). Our results suggest that the 
restricted fibre-type expression profiles of α-actinin-2 and -3 is differently regulated to 
myosin, troponin and tropomyosin in patients with TPM3 mutations compared to age-
matched controls. 
 
Phosphorylation of tropomyosin is increased in patients with mutations in TPM3 
In normal skeletal muscle, a proportion of both α- and β-TPM is phosphorylated at residue 
S283 (28, 29)(Fig. 5Bi). The effect of tropomyosin phosphorylation in skeletal muscle is 
poorly understood, but studies suggest it is important for tropomyosin function by enhancing 
head-to-tail interactions and increasing the cooperative activation of myosin resulting in 
enhanced force production (30). We investigated whether phosphorylation at S283 was 
altered in TPM3 patients (as a possible contributor to muscle dysfunction) by Western blot 
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analysis using an anti-phosphor-S283 specific antibody (Fig. 5Bii shows a representative 
Western blot). Phosphorylation of tropomyosin (all three isoforms were analysed in 
combination) was increased in 6/8 of patients with samples available for analysis, compared 
to five age-matched controls (Fig. 5Biii). However, elevated levels of S283 phosphorylation 
were also observed in patients with mutations in TPM2, ACTA1, DNM2, DMD and DYSF 
(Fig. 5Biiii).  
 
Mutations in DMD (causing Duchenne and Becker muscular dystrophy) and DYSF (causing 
limb girdle muscular dystrophy type-2B) cause muscle fibre breakdown and regeneration. It 
is well documented that tropomyosin phosphorylation is higher during development in 
animals (29), and thus we explored whether increased phosphor-S283 in dystrophic muscle 
was related to fibre re-generation. Using IHC analysis, we established that phospho-S283 
tropomyosin levels did not correlate with fibre-type or with fibre re-generation in control or 
patient biopsies (Supplementary Fig. 2B-C). In TPM3 patients however, levels of phospho-
S283 tropomyosin were specifically elevated in small, slow-twitch myofibres (Supplementary 
Fig. 2A). This suggests that increased phosphorylation of tropomyosin is not specific to 
TPM3 disease, but may be a compensatory response to muscle dysfunction due to a variety of 
mechanisms. 
 
Slow myofibres of TPM3-myopathy patients have reduced maximal force, likely due 
to altered cross-bridge cycling 
In order to understand how muscle weakness develops in TPM3 patients we performed 
contractile studies on single, chemically-permeabilised patient myofibres or small fibre 
bundles by immersing them in Ca2+-containing solutions (see methods regarding details for 
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analysis of bundles). This induces activation of the contractile filaments allowing 
measurement of isometric force production. 
 
First, fibres and fibre bundles were activated at saturating [Ca2+] of pCa 4.5 (~31.6 µM) to 
induce maximal isometric contraction (Fmax, Fig. 6A). A small but significant force deficit 
was observed in slow myofibres and fibre bundles from seven of 10 TPM3-myopathy patients 
compared to pooled control samples (Fmax in all TPM3 patients ranges from 52.17 – 116 
mN/mm2 compared to 143.1±31.8 mN/mm2 in controls, *p<0.01 one-way ANOVA, Fig. 6C 
and D). This force deficit was present despite normalization to the smaller CSA in slow fibres 
of TPM3 patients. Fmax in type-2 fibres was not different from control fibres (106.7-186.7 
mN/mm2 in patient fibres and 147.7±29.34 mN/mm2 in control fibres) (Fig. 6B). In bundles, 
Fmax was lower in bundles with higher slow MHC content in two of three patients 
(Supplementary Fig. 3).  
 
During muscle contraction, a cyclic interaction between the myosin heads and thin filaments, 
followed by a conformational change in myosin, allows the filaments to slide past each other. 
Correct positioning of tropomyosin on actin filaments during the various stages of myosin-
actin interactions is crucial for efficient cross-bridge cycling. To determine if the force deficit 
in slow myofibres of TPM3 patients can be attributed to changes in cross-bridge cycling 
kinetics we measured the rate of tension re-development (Ktr) during maximal activation, 
after a short period of unloaded shortening following by re-stretch (a typical length and force 
trace are presented in Fig. 7Ai). The speed of cross-bridge cycling is physiologically faster in 
type-2 (fast-twitch) fibres compared to type-1 (slow-twitch) fibres (see controls in Fig. 7Aii-
iii). Slow fibres from eight of 10 TPM3 patient biopsies displayed a significant reduction in 
Ktr compared to controls (Ktr in all TPM3 patients ranges from 0.758-1.217 s
-1 compared to 
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1.493±0.25 s-1 in controls, *** p<0.0001, * p<0.01, one-way ANOVA, Fig. 7Aii), whereas 
fast myofibres were not different from control myofibres (Fig. 7Aiii). These results suggest 
that myosin cross-bridge cycling kinetics are altered in slow fibres of TPM3 patients, 
contributing to muscle weakness by reducing the fraction of strongly bound cross-bridges 
during activation. 
 
Fmax is proportional to the force generated by a single strongly bound actin-myosin cross-
bridge and the fraction of myosin heads attached to actin. We assessed active stiffness in 
TPM3 biopsies, a measure proportional to the number of myosin heads strongly attached to 
actin during an isometric contraction (31), to study whether this contributes to muscle 
weakness. We measured active stiffness by performing fast length changes in isometrically 
contracted single myofibres (typical length/force traces are presented in Supplementary Fig. 4 
and a typical patient and control plot of the length change (∆L) versus force change (∆F) is 
presented in Fig. 7Bi and ii, respectively)(32). We observed a trend towards reduced absolute 
active stiffness in type-1 fibres and bundles/hybrid fibres of most TPM3 patients (Fig. 7Biii 
and iiii), which was not present in type-2 fibres (Fig. 7Bv). The change in active stiffness was 
proportional to Fmax, as the difference was not present when stiffness was normalised to 
Fmax (Fig. 7Bvi-viii). Since stiffness is proportional to the number of strongly attached 
myosin cross-bridges, a reduction of active stiffness proportional to force reduction suggests 
that forces per cross-bridge were normal, but, in line with the reduced Ktr, the number of 
strongly attached cross-bridges may be reduced in slow fibres of TPM3 patients, likely 
contributing to muscle weakness. 
 
Ca
2+
-sensitivity of contraction and maximal contractile force are decreased in 
patients with TPM3 mutations 
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Tropomyosin and the troponin complex are pivotal in regulating Ca2+-induced cross-bridge 
cycling during muscle contraction. We assessed the sensitivity to Ca2+ of permeabilised 
fibres, by bathing preparations in incrementally increasing [Ca2+] (pCa 6.2-4.5) and 
measuring the generated contractile force. In slow myofibres and fibre bundles/hybrid fibres 
of all patients, the force-pCa curves were shifted to the right compared to controls (Fig. 8Ai-
ii). As a result, the pCa50, representing the negative logarithm of the [Ca
2+] at which 
preparations produce 50 % of their Fmax, was significantly reduced in type-1 fibres and 
bundles/hybrid fibres from all patients compared to controls (pCa50 type-1: 5.96±0.06 
controls, 5.69±0.04 patients; pCa50 bundles/hybrid:  5.99±0.09 controls, 5.67±0.05 patient, 
Fig. 8Bi-ii). This result indicates that more Ca2+ was required in patient biopsies than control 
biopsies to achieve the same relative force. In contrast, fast fibres from patients and controls 
showed normal Ca2+-activated force production (Fig. 8Aiii, Fig. 8Biii). 
 
Our data demonstrates that slow fibres and in bundles/hybrid fibres from patients with TPM3 
mutations produce on average ~ 63 % of the force produced by control fibres at saturating 
[Ca2+] (pCA 4.5). During a maximal contraction the intracellular [Ca2+] can rise from resting 
levels of ~0.1 µM (pCa 7) to ~10 µM (pCa 5) (33). However, myofibres in vivo rarely 
undergo maximal stimulation and mostly operate at sub-maximal levels, typically resulting in 
[Ca2+] of around 1-5 µM) in type-1 fibres (yellow area in Fig. 8A) (34-36). At these 
physiological Ca2+ levels (pCa 6.0), slow fibres and bundles/hybrid fibres from TPM3 
patients produce on average only 26 % of the force produced by control slow fibres and 
bundles/hybrid fibres (Fig. 8Ci-ii), whereas patient fast fibres produce forces similar to 
controls (Fig. 8Ciii). Thus, our results suggest reduced Ca2+-sensitivity is a significant basis 
for muscle weakness in TPM3-myopathy. 
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Ectopic α-actinin-3 expression in slow myofibres does not correlate with increased 
maximal force 
Four patients with TPM3 mutations at R168 displayed ectopic expression of α-actinin-3 in 
slow myofibres. Since α-actinin-3 expression is associated with increased muscle strength 
and speed (26, 27) we determined whether α-actinin-3 in slow fibres may influence 
contractile properties. We tested if α-actinin-3 expression was more commonly observed in 
fibres with higher Fmax in eight fibres from two patients. However, we found no correlation 
between ectopic α-actinin-3 and force production in these patient fibres (Supplementary Fig. 
5).  
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Discussion 
Mutations in TPM3 cause a range of histopathological patterns and are associated with 
generalised muscle weakness. To date, the cause of muscle dysfunction is not well 
understood in these patients, hindering the development of evidence-based treatments for 
TPM3-myopathies. Thus, we performed extensive phenotypical and functional 
characterization of a large cohort of TPM3-myopathy patients to understand the molecular 
mechanism(s) of their muscle weakness. 
 
The main histological feature of TPM3-myopathy patients in this cohort, and other published 
cohorts (1-3), was a selective hypotrophy of slow myofibres, while other histological features 
such as nemaline rods and caps were rarely present (four of 15 patients). The selective 
hypotrophy and contractile dysfunction of slow myofibres is consistent with the restricted 
slow-fibre expression of α-TPMslow, the main protein expressed from TPM3 in skeletal 
muscle. We confirmed the presence of mutant α-TPMslow in the filamentous fraction of 
patient skeletal muscle via 2D-SDS-PAGE for patients possessing a TPM3 mutation resulting 
in a charge change. In patients with protein aggregates (e.g. nemaline bodies), it has been 
uncertain whether mutant protein is actually incorporated into the sarcomere, or partitions 
into protein aggregates within the muscle fibre. In our study, protein aggregates were not 
observed in biopsies analysed by 2D-SDS-PAGE, suggesting that α-TPMslow mutant protein 
is likely incorporated into sarcomeres causing muscle weakness via a dominant negative 
effect on contractile function. Interestingly, the amount of α-TPMslow mutant protein did not 
correlate well with disease severity in our patient cohort. This may be explained by a number 
of factors influencing disease severity, such as a mutation-specific effect and varying proportions 
of slow fibres in different parts of the same muscle or different muscle groups. 
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Muscle contraction and force production rely on efficient interactions between tropomyosin 
polymers and major binding partners, the troponins and the actin filament, in response to 
Ca2+-influx. In this series of twelve muscle biopsies from TPM3-myopathy patients, we 
showed normal fibre-type expression of the major contractile proteins myosin, actin, troponin 
and tropomyosin. Furthermore, we confirmed normal ratios of the three skeletal muscle 
tropomyosin isoforms according to fibre-type composition for all patients. Our data suggest 
the higher relative abundance of α-TPMslow previously reported in a patient bearing a M9R 
substitution in TPM3 (25, 37) may be a specific property of this mutation, perhaps related to 
its position within the dimerisation domain. In a small number of patients, we observed 
ectopic expression of the fast fibre Z-disc protein α-actinin-3 in slow myofibres. The 
consequence of slow-fibre expression of the fast-fibre α-actinin-3 is not clear, and may relate 
to both metabolic and structural roles of α-actinin-3, though we excluded an overt effect on 
contractile force of single myofibres. Interestingly, similar ectopic expression of α-actinin-3 
was previously observed in some patients with ACTA1 mutations (38) and is thus not specific 
to TPM3-associated disease but could potentially be due to incomplete or abnormal fibre type 
conversion present in some myopathy patients. 
We investigated tropomyosin phosphorylation at residue S283 in our cohort. Tropomyosin 
phosphorylation has mainly been studied in the context of cardiac function (39-42) and to the 
best of our knowledge has not been investigated in skeletal myopathy patients. In vitro 
studies suggest phosphorylation strongly affects tropomyosin properties [e.g. stronger head-
to-tail interaction, enhanced troponin binding, higher myosin ATPase activity and long-range 
cooperative activation of myosin-thin filament binding (30, 43, 44)]. We showed 
tropomyosin phosphorylation was commonly increased in a wide range of genetic muscle 
disorders including TPM3-myopathy. However, the cause of this up-regulation and the effect 
on skeletal muscle contractility is unclear. The p38-MAPK (mitogene-activated protein 
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kinase) and ERK (extracellular signal-related kinase) signalling pathways are likely involved 
in tropomyosin phosphorylation of cardiac muscle and non-muscle cells, respectively (45-
47). In skeletal muscle, these pathways regulate exercise-induced adaptive responses on gene 
expression (reviewed in 48), suggesting tropomyosin phosphorylation may be involved in 
remodelling or adaptation to cellular stress.  
Most reported TPM3 substitutions lie within or near actin-binding domains, with several 
substitutions believed to influence direct electrostatic interactions with actin in the “off” state 
[when tropomyosin blocks myosin binding sites on the actin filament e.g. R91, R168, R245 
directly interact with actin D25 (49-51)]. Our data and previous studies have shown that 
many tropomyosin substitutions indeed affect binding to actin-filaments (52-55). Thus, 
altered actin-binding likely represents a common mechanism by which tropomyosin mutants 
alter sarcomeric function, perhaps related to the Ca2+-activated movement of tropomyosin 
between the “on” and “off” position during cross-bridge cycling (51, discussed in 56). 
 
Recent studies have attempted to predict the effect of mutations on actin-tropomyosin 
interactions and the resulting contractile abnormality, classifying them as “gain-of-function” 
changes (hyper-contractile phenotype, shift towards “on” state) and “loss-of-function” 
changes (hypo-contractile phenotype, stabilizing the “off” state) (50, 57, 58). Most mutations 
in our cohort are predicted to cause a “loss-of-function” (e.g. decreased Ca2+-sensitivity and a 
hypocontractile phenotype). The only exception is TPM3 K169E, predicted to favour the 
“on” position and enhance myosin-actin binding (50, 57)]. This phenotype was confirmed in 
reconstituted thin filaments in vitro (50). However, isolated slow myofibres and fibre bundles 
of all TPM3 patients (including Patient 1 carrying the K169E mutation), showed reduced 
Ca2+-sensitivity of contraction. Our data are consistent with the patient phenotype described 
in (1) and do not support the hyper-contractile phenotype of the K169E mutation present in in 
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vitro assessment of isolated filaments (50). This discrepancy may be explained by the greater 
complexity of single-fibre contractility studies, a setting that evaluates the combined 
contributions of actin, tropomyosin and troponin binding and regulatory proteins within a 
mature myofibre, which may also have undergone adaptive responses to disease. These may 
not be mirrored by in vitro actin motility studies or predictions via molecular modelling. 
Additional factors, such as interactions with other sarcomeric proteins like the troponin 
complex (59), may also contribute. Additionally, a recurrent mutation in TPM3, R168H, was 
found to reduce [current study and (21)] or increase Ca2+-sensitivity (20) in different patients 
with the same mutation. The cause for this patient to patient variability remains to be 
established. 
In our study, we identified two major abnormalities in contractile performance that we 
believe directly underpins weakness in TPM3-myopathy. Firstly, all patients exhibited 
reduced Ca2+-sensitivity of contraction in slow myofibres, likely resulting in a significant 
reduction in the contractile force generated at physiological, sub-maximal activation of 
muscle. Secondly, slow myofibres demonstrated a significant reduction in cross-bridge 
cycling kinetics and a small reduction in active stiffness (assesses the number of strongly 
bound myosin-actin cross-bridges) – meaning that myosin less effectively and less stably 
transits along actin filaments during contraction.  Collectively, these two abnormalities likely 
cause insufficient force production during a normal action potential resulting in slow fibre 
weakness. 
The selective dysfunction of slow myofibres in our cohort demonstrates the importance of 
assessing the two fibre types separately, and raises the question as to why fast myofibres are 
not able to compensate for dysfunctional slow myofibres. Inherent differences exist between 
the two fibre types. Slow myofibres are less fatigable than fast myofibres, probably due at 
least in part to larger numbers of mitochondria and a greater capacity for oxidative 
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metabolism (60, 61). Additionally, fast myofibres have a higher ATP consumption. Particular 
muscle groups, such as respiratory muscles, rely on slow fibres to produce sustained, low 
intensity contractions. Substantial weakness of respiratory muscles is common in TPM3 
patients, and effective treatments that specifically target slow muscle fibre dysfunction may 
ameliorate respiratory insufficiency. 
In summary, contractile function was commonly impaired in TPM3-myopathy patients. In 
particular, we showed reduced force generation caused by altered cross-bridge cycling 
kinetics and reduced Ca2+-sensitivity of muscle contraction. The identification of abnormal 
Ca2+-sensitivity suggests the use of Ca2+-sensitisers may present a viable therapeutic 
approach for TPM-related myopathies. To date, a number of agents are known to be effective 
at improving Ca2+-sensitivity in isolated skeletal myofibres from various species including 
bovine, human, mouse and rabbit (21, 62-65). Additionally, Ca2+-sensitisers were able to 
ameliorate muscle dysfunction in a rat model of myasthenia gravis (62) and isolated skeletal 
myofibres from congenital myopathy patients with mutations in TPM3, TPM2 and NEB (21, 
63). This therapeutic approach appears to be promising; however, most of these agents target 
the fast troponin isoforms and are unlikely to ameliorate slow fibre dysfunction. A Ca2+-
sensitiser acting on slow skeletal/cardiac troponin-C did not improve Ca2+-sensitivity in 
skeletal myofibres in a recent study, suggesting that new compounds targeting slow myofibre 
dysfunction have yet to be developed (66). Also, it appears that TPM2 and TPM3 mutations 
can either increase or decrease Ca2+-sensitivity in a patient and mutation-specific manner 
(overview in Supplementary Tab. 4), thus Ca2+-sensitisers will only be useful in a subset of 
patients. Patients with increased Ca2+-sensitivity display a hyper-contractile clinical 
phenotype (21, 54), suggesting treatment with Ca2+-sensitisers must be tightly regulated to 
ensure appropriate muscle function and avoid side effects. 
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Materials and Methods  
Study approval 
This study was approved by the human ethics committees of the Stollery Children’s Hospital, 
Edmonton, Canada (ID: 5856), Royal Children’s Hospital, Melbourne, Australia (ID: 
21102A), Children’s Hospital at Westmead, Sydney, Australia (ID: 2000/068, 10.CHW.45), 
University of Sydney, Australia (ID: 01/11/50) and Boston Children’s Hospital Institutional 
Review Board (03-08-128R). Informed consent was obtained from all individuals. 
Molecular modelling 
Molecular modelling was based on the 7 Ångstroms resolution crystal structure of an α-
TPMfast dimer isolated from adult porcine ventricles (RCSB Protein Data Bank 1C1G, 
Whitby and Phillips (23)). Molecular graphics were created with Swiss-PDB Viewer v4.1.0 
(67). 
 
Antibodies 
Mouse anti-sarcomeric actin (5C5, 1:100 for immunohistochemistry [IHC] and 1:10000 for 
Western blot), fast myosin [MY32, 1:800 for IHC, tropomyosin (TM311, 1:20,000 for 
Western blot and 1:800 for IHC), troponin-Tfast (TNNT3, 1:30 for IHC and 1:1000 for 
Western blot) were obtained from Sigma Aldrich. S283-phosphorylated tropomyosin was 
detected using the rabbit anti-Tm-pS283-050 (1:500 for Western blot and 1:30 for IHC, 21st 
Century Biochemicals) and slow myosin antibodies were obtained from Chemicon (1:800 for 
IHC and 1:7000 for Western blot). Polyclonal α-actinin-3 antibodies were produced in-house 
(antibody 5B3 diluted 1:50 for IHC and antibody 5A2 1:1500 for Western blot) (68). 
Troponin-Islow (MYNT-S, diluted 1:10 for IHC) and fast (MYNT-F, diluted 1:150) 
antibodies were kindly supplied by Takeshi Nakamura, Japan. Troponin-Tslow antibodies 
(CT3) were obtained from the Developmental Studies Hybridoma Bank, University of Iowa 
Page 62 of 88Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
(diluted 1:50 for IHC). Cardiac actin and neonatal myosin heavy chain (MHC) antibodies 
were obtained from American Research Products Inc, USA and Novocastra Laboratories Ltd, 
UK, respectively. 
 
IHC and Zenon labelling  
IHC was performed as described previously (69). Sections were either fixed as described in 
(37) (MYNT-S) or for 10 min in 3% PFA (MYNT-F, CT3 and TNNT3) or used unfixed 
(other antibodies). A Zenon mouse IgG labelling kit (Molecular Probes) was used to directly 
label primary antibodies with different fluorophores for co-staining with two mouse 
antibodies as per manufacturer’s instructions (either MHC type-2A and type-1 [Fig. 5] or 
neonatal MHC and cardiac actin [Supplementary Fig. 2C]). Staining was imaged using 
standard fluorescence microscopy. 
 
Fibre morphometry 
Fibre morphometry was performed on cryo-sections stained for myosin ATPase (70)] or 
following IHC for MHC isoforms. At least 200 fibres, visible in two distant fields of the same 
section were analysed using ImagePro Plus 4 software (Media Cybernetics). The greatest 
distance between opposite sides of the narrowest aspect, the MinFeret diameter, was 
measured to obtain the fibre diameter from a cross sectional cut. The percentage fibre-size 
disproportion (%FSD) was calculated as described in (1) and slow fibre area was calculated 
assuming circular shape of myofibres. 
 
Western blot and 2D-polyacrylamide gel electrophoresis (2D-SDS-PAGE) 
Western blot methods were based on (71) and tropomyosin isoforms were resolved as 
described in (54). Extraction of the filamentous protein pool from skeletal muscle sections 
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and 2D-SDS-PAGE to determine mutant tropomyosin expression were performed as 
described previously (14, 72). 
 
Protein sources and actin-tropomyosin co-sedimentation 
We employed site-directed mutagenesis to produce wild-type and mutant (R168C, K169E) α-
TPMslow baculoviruses to infect Sf9 insect cells using the baculovirus expression method as 
described previously (73, 74). 
Filamentous actin was prepared from actin-acetone powder isolated from rabbit muscle (75) 
and a 1 µM stock with 1 µM phalloidin and 0.1 mM ATP was used for experiments.  
All protein stocks were prepared in and dialyzed against a buffer containing 100 mM KCl, 50 
mM Imidazole, 8 mM MgCl2, 2 mM EDTA, 10 mM DTT and 0.5 mg/mL ultrapure bovine 
serum albumin (BSA, Sigma). Ten µM tropomyosin stocks were cleared of aggregates by 
ultracentrifugation at 603,180 x g (Sorvall M120-SE centrifuge, S100AT6-0199 rotor) for 20 
min at 4 °C. Ten nM actin were co-sedimented with incremental amounts of tropomyosin 
(50-1000 nM) in 1 mL reaction volume at 51,427 x g for 1.5 hr at 25 °C (Sorvall Evolution 
RC centrifuge, F20-Micro rotor) in siliconised polypropylene tubes. The pelleted fractions 
were solubilised in loading buffer and loaded on 4-15 % Criterion TGX gels (Biorad). 
Densitometry analysis on actin and tropomyosin bands was performed using GeneTools 4.0 
software (Synoptics Ltd). Values were corrected for sedimentation in the absence of actin and 
plotted as the ratio tropomyosin/actin vs. total [tropomyosin] added. Data were fitted to a Hill 
equation to determine the binding constant Kd and Hill’s coefficient h using GraphPad, Prism 
(Version 5.01). 
Contractile measurement of myofibres isolated from frozen human muscle biopsies 
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Small fractions of frozen muscle biopsies were thawed as described previously (63) in a 
solution containing 50 % glycerol and 50 % Ca2+-free relaxing-solution (100 mM BES, 6.97 
mM EGTA, 6.48 mM MgCl2, 6 mM Na2ATP, 1 mM DTT, 40.76 mM K-propionate, 14.5 mM 
creatine phosphate, 0.5 mM PMSF, 10 µM E64, 40 µM leupeptin, pH 7.1 and pCa 9 at 15 
°C). 
For contractile measurements, single fibres or small fibre bundles [~0.07 mm2 cross sectional 
area (CSA) and ~ 0.5 mm length] were dissected in glycerinating solution at 4 °C. Fibre 
bundles were prepared if the fibre CSA was too small for reliable force measurements. 
Aluminium T-clips were attached to both ends of the preparation followed by chemical 
skinning in glycerinating solution containing 1 % TritonX-100 for 10 min (single fibres) or 
30 min (bundles) at 4 °C. The preparations were then stored at 4 °C in glycerinating solution 
until mounting onto a permeabilised fibre apparatus between a length motor and a force 
transducer (ASI 802D, ASI 403A, ASI 315C-I, respectively, Aurora Scientific Inc., Canada) 
in relaxing-solution. All force measurements were performed at sarcomere lengths of 2.5 µm 
[optimal myofilament overlap, (76)] and at a temperature of 20 °C (bath temperature 
controller ASI 825A, Aurora Scientific). The sarcomere length was set and the CSA was 
measured as described in (63). 
 
Prior to [Ca2+]-induced activations preparations were pre-activated for 1 min in 100 mM 
BES, 0.1mM EGTA, 6.42 mM MgCl2, 6 mM Na2ATP, 41.14 mM K-propionate, 14.5 mM 
creatine phosphate, 6.9 mM HDTA (pH 7.1 and pCa 9 at 15 °C). Maximal isometric 
contraction (Fmax) was measured by bathing fibres in saturating [Ca2+] buffer (100 mM BES, 
7 mM CaEGTA, 6.28 mM MgCl2, 6 mM Na2ATP, 40.64 mM K-propionate, 14.5 mM 
creatine phosphate, pH 7.1 and pCa 4.5 at 15 °C) until a force plateau was achieved. The 
maximal specific force (Fmax at pCa 4.5 normalised to the CSA) is presented in this study. 
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Force/pCa curves and pCa 50 were measured as described in (20). The rate constant of 
tension re-development (Ktr) was measured by allowing the preparations to shorten to 70 % of 
the initial length for 30 ms followed by re-stretch to 100 % and fitting the data to a mono-
exponential function using Labview (National Instruments, USA) as described in (20). Active 
stiffness was measured immediately after the Ktr protocol as described previously (32, 77). In 
brief, we measured the force response (F1) to six 2 s length changes (∆L: +0.3 %, +0.6 %, 
+0.9 %, -0.3 %, -0.6 %, -0.9 %; Supplementary Fig. 4). ∆L was plotted against the force 
changes (∆F) and a linear regression was fitted to obtain the slope using Graph Pad, Prism 
(Version 5.01). 
 
The MHC content of measured fibres was determined as described previously (63) and the 
proportion of each MHC was determined by densitometry. Single myofibres/fibre bundles 
containing exclusively slow MHC (>90 % type-1), exclusively fast MHC (>90 % type-2A or 
2X) or a mixture of both (11–90 % type-1 or type-2A/2X) were grouped for analysis. The 
contractile properties of bundles and hybrid fibres containing a mix of type-1 and type-2A/2X 
MHC represent the average properties of both fibre types. The Ktr in bundles/hybrid fibres is 
highly variable due to the physiologically difference in type-1 or type-2A/2X fibres and was 
therefore not presented. Preparations were excluded from the analysis if the Fmax decreased 
>15 % during the protocol. Single myofibres from eight control biopsies (age 6-54 y) and 
bundles from two control biopsies (aged 0.6 and 6 y) were pooled for statistical analysis. 
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Legends to Figures 
Fig. 1: Dominant mutations in TPM3 affect amino acids located within or close to actin 
binding domains 
Tropomyosins form α-helical coiled-coil dimers via a seven residue repeat motive in their 
amino acid sequence [a-b-c-d-e-f-g] as illustrated in (A-B). Positions a and d (blue) are 
usually hydrophobic and create a hydrophobic pocket between two tropomyosin chains 
facilitating dimerisation in a “knobs-into-holes” fashion. Positions g and e (green) are 
occupied by charged amino acids that further stabilise the dimer through inter-helical salt 
bridges. Positions b, c and f (yellow) localise to the surface of the TM dimer and likely 
modulate interactions with protein binding partners such as actin and troponin. (C) A ribbon 
model of a whole tropomyosin dim r with the actin binding domains marked in pink on one 
strand. The residues affected by dominant mutations in TPM3 are shown. All affected 
residues are located in or close to actin binding domains. Eight mutations affect residues in 
the b, c or f positions of the repeat (yellow). Three mutations affect residues in the a and d 
position (blue) and two affect residues in the g and e position (green). RCSB Protein Data 
Bank access code for protein structure model is 1C1G [tropomyosin dimer, Whitby and 
Phillips (23)]. Swiss-PDB Viewer v4.1.0 was used to create molecular graphics (67).  
 
Fig. 2: TPM3-myopathy patients have slow fibre hypotrophy and a deregulation of slow 
and fast muscle fibre proportions 
(A) ATPase pH 4.6 stained muscle cross section of one control and four patients with 
mutations at residue R168, of α-TPMslow demonstrating a selective hypotrophy of slow type-1 
myofibres. Fast type-2 fibres are between 1.7 and 5.2 times larger in size than type-1 fibres, 
whereas age-matched controls (age between 0.8 -57 y) showed roughly equally sized fibres 
(B). This corresponds to a fibre-size disproportion (FSD) between 41 % and 78.3 % (C). 
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Patients with TPM3 mutations show an abnormal fibre type distribution ranging from 
complete type-1 fibre predominance (A: Patient 10) to type-2 fibre predominance (A: Patient 
8). (D) In the majority of control biopsies between 40-60 % of the CSA is composed of type-
1 fibres. TPM3-myopathy patients have either below 40 % or above 60 % type-1 fibre area. 
Fibre type measurements were performed twice at different times from the same biopsy in 
Patients 2, 3c, 6b and 8 (also see Supplementary Tab. 2) and the plotted values represent the 
average of both measurements. All images were taken at 100x magnification. Fibre size 
measurements and further information on patient and control biopsies are summarised in 
Supplementary Tab. 2. 
 
Fig. 3: Tropomyosin isoform ratios are not commonly altered and mutant α-TPMslow is 
expressed in TPM3-myopathy patient muscle 
(Ai) A representative Western blot of TPM3-myopathy patient and control muscle tissue 
showing the three skeletal muscle tropomyosin isoforms (β-TPM, α-TMfast and α-TPMslow). In 
normal muscle, type-1 fibres contain about 50:50 α-TPMslow/β-TPM and type-2 fibres contain 
about 50:50 α-TPMfast/β-TPM. Most sample had β-TPM and α-TPMfast/slow levels consistent 
with the relative proportion of type-1 and type-2 fibres present in the sample (% type-1 fibre 
area was determined from ATPase staining, see Supplementary Tab. 2). Only one patient 
(TPM3 M9R mutation, lane 5) had reduced β-TPM levels and increased expression of α-
TPMslow relative to other tropomyosin isoforms and the fibre type proportion in the biopsy as 
described previously (25). (Aii-iiii) Densitometry analysis of Western blots from 10 patients 
with mutations L100M (n=3), R168C (n=1), R168G (n=1), R168H (n=3), K169E (n=1), 
R245G (n=1) was performed to quantify the proportion of each tropomyosin isoform as a 
percentage of total TPM. The relative abundance of each isoform was plotted against the % 
type-1 fibre area (measurements from TPM3 M9R patient are not included). (Aii) β-TPM 
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levels are about 50 % of total tropomyosin in patients and controls. (Aiii-iiii) About 50 % of 
tropomyosin is α-TPMfast/slow, but the amount of these fibre-type specific isoforms correlates 
closely with the % type-1 fibre area in both patients and controls (positive correlation for α-
TPMslow, negative correlation for α-TPMfast). Linear regression analysis showed that slopes of 
patient and controls were not significantly different for any of the three isoforms (p=0.4997, 
0.9538 and 0.4595 for α-TPMslow, α-TPMfast and β-TPM, respectively). (B) Isoelectric 
focusing of patient and control muscle lysates shows three spots (corresponding to β-TPM, α-
TPMfast, α-TPMslow). An additional spot (marked by an arrow) consistent with the predicted 
isoelectric point (pI) of each mutation (as annotated, wild-type α-TPMslow is 4.69) is present 
in patient biopsies. Mutant α-TPMslow accounted for 27-45% of total α-TPMslow in different 
patient biopsies (annotated in the blot, the proportion of each tropomyosin in patient slow 
fibres is given in Supplementary Tab. 3). Note the ratio of expression of α-TPMfast/slow 
depends on the percentage of slow and fast myofibres in the biopsy (e.g. Patient 8 (R168C) 
mainly contains fast myofibres). Picture 3 from the left in (B) is reprinted from Neuromuscul 
Disord, 20/7 Waddell et al., Evidence for a dominant negative disease mechanism in cap 
myopathy due to TPM3, 464-466, Copyright (2010), with permission from Elsevier. 
 
Fig. 4: Mutant α-TPMslow R168C proteins has a reduced affinity to filamentous actin 
Phalloidin stabilised actin filaments were co-sedimented with incremental amounts of 
tropomyosin and the pelleted fractions were analysed by SDS-PAGE. (A) A representative 
SDS-PAGE of wild-type α-TPMslow protein as was used for densitometry analysis. (B) The 
ratio of TPM/actin was plotted vs. total [TPM] added and a Hill’s equation was fitted. The Kd 
was increased in α-TPMslow R168C compared to α-TPMslow wild-type and K169E suggesting 
weaker binding affinity to actin (771.4±188.6 nM, 180.2±37.6 nM, 164.0±110.6 nM for α-
TPMslow R168C, wild-type and K169E, respectively). The Hill’s coefficient h and maximal 
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binding (Bmax) was similar in all three proteins (h = wild-type 4.471±3.0, R168C 3.308±2.4, 
K169E 1.602±1.3; Bmax wild-type 0.489±0.055, R168C 0.431±0.078 and K169E 
0.443±0.156). Values are best-fit values ± 95% confidence interval. 
 
Fig. 5: TPM3 patients show increased phosphorylation of tropomyosin and ectopic 
expression of fast fibre specific α-actinin-3 in slow myofibres 
(A) Consecutive sections were labelled with type-1 and type-2a MHC (blue and green, co-
labelled respectively), type-2 MHC (red), α-actinin-3 (green) and troponin-Tfast (green) (the 
same fibre in multiple stains is indicated by a white arrow). Troponin-Tfast is only expressed 
in fast fibres as expected. Abnormal expression of α-actinin-3, a fast fibre specific Z-disc 
protein, was observed in type-1 myofibres of Patients 10, 4 and 6a (yellow stars). The biopsy 
of Patient 6b showed similar abnormalities but is not shown in this panel. Other patients had 
normal expression of α-actinin-3. Staining of Patient 1 and 8 are representative for these 
patients. (Bi) S283 is conserved and can be phosphorylated in all three sarcomeric 
tropomyosin proteins. (Bii) We assessed the level of S283 phosphorylation (pTPM) and total 
tropomyosin protein levels by duplicate Western blot and equal loading was confirmed by 
using sarcomeric actin (s Actin) (representative Western blot shown). The phosphorylation 
status of all three tropomyosin isoforms was determined by densitometry and normalised to 
the total tropomyosin levels. The graph shows phosphorylation levels normalised to the 
control average in (Biii) TPM3 patients and (Biiii) patients with congenital myopathies and 
muscular dystrophies due to mutations in TPM3, TPM2, ACTA1, DNM2, DMD and DYSF. 
Horizontal lines and error bars represent mean and standard deviation. Phosphorylation was 
commonly increased in both TPM3 patients and patients with other genetic causes of muscle 
disease. Statistical analysis was only performed on patients with the R168H mutation due to 
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insufficient data points for other groups. Phosphorylation was significantly higher in patients 
with the R168H mutation compared to controls (*p<0.05, Mann-Whitney U test).  
 
Fig. 6: The force generation at saturating [Ca
2+
] is decreased in TPM3-myopathy 
patients 
Maximal force generation (Fmax) measured at pCa 4.5 and sarcomere length of 2.5 µm, 
normalised to fibre CSA. (A) A typical force trace from a patient (Patient 6) and control type-
1 fibre. Most TPM3 patients showed a significant force deficit in type-1 myofibres (C) 
whereas type-2 fibres produced similar maximal force compared to controls (B). In hybrid 
fibres and fibre bundles all patients had a slightly lower force average, however only Patient 
1 showed a significant force deficit (D). Cslow = Control type-1 fibres (pooled from eight 
biopsies aged: 11-54 y), Cfast = Control type-2 fibres (pooled from eight biopsies aged: 6-54 
y), Ch/b= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 11-54 y) and 
small fibre bundles (bundles were taken from two biopsies of 0.9 y and 6 y old controls). P = 
Patient. The black line in (B-D) indicates the average. *** p<0.0001, * p<0.01, one-way 
ANOVA. 
 
Fig. 7: The force deficit in TPM3-myopathy patients is likely due to abnormal cross-
bridge cycling 
We assessed the rate of tension re-development (Ktr) (A)) and active stiffness (B) in TPM3-
myopathy patients to investigate if the force deficit in patient type-1 fibres was due to altered 
cross-bridge cycling. A typical Ktr trace of a patient (Patient 6) and a control are shown in 
(Ai). The Ktr in single myofibres from TPM3 patient biopsies and control biopsies are shown 
in (Aii) (type-1) and (Aiii) (type-2). Note that due to different MHC-ATPase properties the 
Ktr is physiologically higher in type-2 than in type-1 fibres. (Aii) The type-1 fibres of most 
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TPM3 patients showed a significant decrease in Ktr compared to control type-1 fibres 
(exceptions: Patient 1, 2 and 3a (*** p<0.0001, * p<0.01, one-way ANOVA) (Aiii) The type-
2 fibres were not different to control type-2 fibres, with the exception of Patient 6 which 
showed a small decrease in Ktr. (B) Active stiffness was analysed by plotting the length 
changes (∆L) against the force changes (∆F) and fitting a linear regression to the data. A 
representative graph of type-1 fibres from Patient 4 and from controls is shown in (Bi: 
absolute length change) and (Bii: length change/Fmax). Graphs from other all other samples 
are presented in Supplementary Fig. 6. Error bars represent standard deviation. (Biii-v) The 
slope of the linear regression was not significantly different from controls in all fibre-types in 
most patients with the exception of type-1 fibres or bundles/hybrid fibres of Patient 1, 2 and 7 
where stiffness was reduced (*p<0.01 ,**p<0.001 ,*** p <0.0001, one-way ANOVA). 
However, a trend towards a small reduction was present in type-1 fibres and bundles/hybrid 
fibres of most patients (Biii-iiii). (vi-vii) When ∆F was normalised to Fmax the slope was not 
significantly different from controls with the exception of P3c, which showed an increase in 
the slope (I, *** p <0.0001, one-way ANOVA). Error bars represent standard deviation. Cslow 
and Cfast = Control type-1 and type-2 fibres (pooled from eight biopsies aged: 11 - 54 y), Ch/b 
= Control hybrid fibres (contain a mix of type-1 and type-2 MHC, age 6 - 54 y) and small 
fibre bundles (bundles were taken from two biopsies of 0.9 y and 6 y old controls). The black 
line in all scatter plots indicates the average. 
 
Fig. 8: Ca
2+
-sensitivity is decreased in TPM3-myopathy patients resulting in reduced 
specific force generation at physiological [Ca
2+
] 
(A) Specific force generation at incremental [Ca2+] in skinned type-1 fibres (i), hybrid fibres 
or bundles (ii) and type-2 fibres (C) shown as percent of Fmax fitted to a variable slope log 
(dose) response curve. Note the rightward shift of the force/pCa curve in type-1 fibres, hybrid 
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fibres/bundles in TPM3 patients, whereas type-2 fibres were not different to controls. The 
dotted lines indicate the pCa50 ([Ca2+] required to achieve 50 % of maximal force) and the 
yellow area indicates physiological cytoplasmic [Ca2+] during muscle contraction (between 1 
- 5 µM) (B) The pCa 50 was significantly higher in type-1 fibres, hybrid fibres/ bundles of 
TPM3 patients compared to controls and type-2 fibres of TPM3 patients. (C) Specific force 
generation measured at pCa 6.0 (1 µM, physiological calcium). The force was significantly 
lower in (i) type-1 fibres and (ii) hybrid fibres/bundles of all TPM3 patients, but was not 
different from controls in (iii) type-2 fibres. Cslow and Cfast = Control type-1 and type-2 fibres 
(pooled from eight biopsies aged: 11-54 y), Ch/b = Control hybrid fibres (contain a mix of 
type-1 and type-2 MHC, age 6-54 y) and small fibre bundles (bundles were taken from two 
biopsies of 0.9 y and 6 y old controls). The black line in the scatter plot indicates the average 
and error bars in force/pCa curves are standard deviations. *** p<0.0001, * p<0.01, one-way 
ANOVA. P=Patient, C= control. 
 
Tables 
Table 1: Patient cohort with dominant TPM3 mutations 
P Mutation 
in TPM3 
Disease Muscle 
type 
Sex Age at 
biopsy 
Clinical 
classification 
Publication Contractile 
studies 
1 K169E CFTD Q M 16 m moderate (1): P 2 Y 
2 R245G CFTD Q M 20 m moderate (1): P 1 Y 
3a L100M CFTD Q F 3 y mild (1): P 5 Y 
3b L100M CFTD B M 30 y mild (1): P 7 Y 
3c L100M CFTD B M 36 y mild (1): P 8 Y 
4 R168G CFTD Q M 10 y mild (1): P 3 Y 
5 R168H  CFTD Q F 40 y mild unpublished Y 
6a R168H NM D F 20 y mild (1): P 10 N 
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6b R168H  CFTD ? M 56 y mild (1): P 11 Y 
7 R168C Cap ? M 3 y mild (14): P 1 Y 
8 R168C CFTD Q F 19 y moderate (1): P 9 Y 
9 M9R NM Q F 21 y mild (8); (37): P 1 N 
10 R168H NM D M 53 y mild (13): P III-4 N 
11 E241K CFTD Q F 0.5y moderate (2): P 311-1 N 
12 R91P CFTD Q F 0.5y severe (2): P 913-1 N 
Q=Quadriceps, B = Biceps, D = Deltoid, P = Patient 
 
Abbreviations 
α-tropomyosinslow      α-TPMslow 
α-tropomyosinfast      α-TPMfast 
bovine serum albumin     BSA 
β-tropomyosin       β-TPM 
congenital fibre-type disproportion    CFTD 
cross sectional area      CSA 
immunohistochemistry     IHC 
−log of molar free [Ca2+]     pCa 
maximal isometric contraction     Fmax 
myosin heavy chain      MHC 
percentage fibre-size disproportion     % FSD 
phosphate buffered saline      PBS 
two-dimensional SDS polyacrylamide gel electrophoresis 2D-SDS-PAGE 
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Fax: +61 2 9845 3489 
Email: michaela.kreissl@sydney.edu.au 
 
20 July 2015 
 
 
Dear Editor, 
 
 
Re: Manuscript number: HMG-2015-W-00595: Yuen et al., ‘Muscle weakness in TPM3-myopathy is due to reduced Ca
2+
-
sensitivity and impaired acto-myosin cross-bridge cycling in slow fibres.’ 
 
Thank you for the timely review of our manuscript.  Below I have addressed your queries and those of the reviewer’s 
below.  
 
Kind regards,  
 
Michaela Yuen  
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1. FORMATTING ERRORS 
 
I have corrected the following formatting errors: 
 
TITLE PAGE 
The corresponding author was designated with an asterisk (*) and address, telephone, FAX, and email address were listed. 
 
MANUSCRIPT 
TIMES NEW ROMAN font was used for all text and text was double-spaced. 
 
REFERENCES 
References were edited to comply with the Human Molecular Genetics format (specifically, all abbreviated words in journal 
titles were punctuated, i.e. Hum. Mol. Genet. NOT Hum Mol Genet.) 
 
 
2. REVIEWERS' COMMENTS 
 
Reviewer: 1 
 
Question 1: I am intrigued by the mutant/wt expression data.  I would have predicted (a) that mutant protein is produced 
and (b) that its levels would correspond to phenotype.  The latter point does not seem to come out in the experimentation, 
as the samples with the most severe clinical phenotype have the lowest mutant protein levels. (c) Were the overall levels 
of TPM3 reduced in those samples?   
 
Redress  to 1(a) and (b): Yes, one might reasonably expect mutant protein levels to correlate with clinical disease severity. 
However, many additional factors likely determine the overall weakness observed in a TPM3-myopathy patient. 
 
For instance, TPM3 is specifically expressed in slow muscle fibres. The area occupied by slow fibres and thus the number of 
fibres expressing the mutant protein may vary in different parts of each patients biopsy (see Table 1 below) and in different 
muscles in the same patient (Ilkovski et al, 2008). Thus in addition to taking into account the amount of mutant protein, one 
has to consider the number of slow fibres in the affected muscle groups to correlate clinical severity with the presence of 
mutant protein. This is further complicated by the specific defects exerted by each mutation.  
 
Interestingly, a shift towards slow fibre predominance is commonly observed in our cohort and in other congenital 
myopathies. This would result in more fibres expressing mutant protein, however, high numbers of slow fibres did not 
correlate with more severe disease (see Table 1). On the contrary, more severely affected patients were among the patients 
with the lowest slow fibre area (marked in yellow in Table 1). We believe this suggests fast fibre predominance is unable to 
compensate for slow fibre dysfunction and may confer a more severe presentation. 
  
We inserted the following comment in the manuscript to address this question (paragraph 2 of the discussion): 
“Interestingly, the amount of α-TPMslow mutant protein did not correlate well with disease severity in our patient cohort. 
This may be explained by a number of factors influencing disease severity, such as a mutation-specific effect and varying 
proportions of slow fibres in different parts of the same muscle or different muscle groups.” 
 
Redress to 1(c): Concerning potentially reduced levels of α-TPMslow: We observed a strict correlation of α-TPMslow  relative to 
slow fibre cross sectional area in our entire cohort, with the exception of patient 12 where poor muscle quality did not allow 
fibre typing of the muscle.  
 
 
Question (2): Is there any way to examine the ratio of WT/mut in the remaining samples?  Perhaps by proteomics?   
 
Redress to (2): We agree, knowing mutant and wild type protein ratios for the remaining samples would be useful but 
technical limitations of mass spectrometry (MS) preclude these studies.  We determined the mutant/wild type ratio in all 
samples that expressed α-TPMslow (presence of sufficient number of slow fibres) and resulted in a charge change as required 
for separation from wild type protein via 2D-PAGE (see Table 1). We inquired in our proteomics facility about the use of 
mass spectrometry for analysis of mutations without a charge change, but were advised tropomyosin presents a poor 
candidate for MS due to the abundance of trypsin sites.  But also, there is no guarantee (for any protein) that the particular 
subset of fragments ionized and detected by MS will include a fragment bearing a missense mutation of interest. Therefore, 
we were unable to pursue any missense mutations without a charge change. 
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Table 1: Mutant α-TPMslow expression and slow fibre area do not correlate with clinical severity 
P Mutation in 
TPM3 
Age at 
biopsy 
Clinical 
classification 
IEF result Type 1 fiber area* 
1 K169E 16 m moderate 38% mutant 23.3 
2 R245G 20 m moderate no/very low levels of TPM3 
due to fiber typing (6.4% type 
1 fiber area in biopsy 
available) 
20.5 
6.4 
3a L100M 3 y mild no charge change 61.8 
3b L100M 30 y mild no charge change 73.4 
3c L100M 36 y mild no charge change 37.3  
25.9 
4 R168G 10 y mild 39% mutant 74.6 
5 R168H  40 y mild no charge change N/D 
6a R168H 20 y mild no charge change 62.8 
6b R168H  56 y mild no charge change 16.3  
39.6 
7 R168C 3 y mild published in Waddell et al 
2010 ~50% mutant 
100 
8 R168C 19 y moderate 37% mutant 13.7  
5.1 
9 M9R 21 y mild published in Ilkovski et al 
2008 ~50% mutant 
N/D 
10 R168H 53 y mild no charge change 100 
11 E241K 0.5y moderate 90% mutant 27.9 
12 R91P 0.5y severe 23% mutant N/D due to insufficient 
sample quality 
*two values are stated for a patient when fibre typing was performed twice, at different times and on different parts of the 
biopsy 
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Question (3): Can one evaluate the amount of mut/WT protein in the non filamentous fractions?  Perhaps much of the 
mutant protein is not being incorporated. 
 
Redress to (3): This is a good suggestion. Unfortunately, we did not determine mutant/wild type levels in the soluble 
fraction at the time these experiments were performed and due to limited amount of biopsy material we are unable to 
perform these experiments retrospectively. We sincerely hope this will not detract from the overall quality of the paper. 
 
 
Question (4): In terms of the actin co-sedimentation assay, given that this is a dominant disease and that the mutant and 
WT proteins co-exist, it seems like the most accurate way to do this experiment would be to look at the data using 
equimolar (and skewed) ratios of WT/mut and then measuring actin co-sedimentation.  It is known for some other 
dominant diseases that the effect of mut protein can be quite different when all polymers are composed of mutant protein 
vs combo polymers of WT/mut proteins. 
 
Redress to (4): Actin-TPM co-sedimentation assays are a useful tool in evaluating the interaction of actin and mutant TPM 
in an isolated system and can provide important insights into specific actin-binding defects. Mutant α-TPMslow, wild type α-
TPMslow and wild type β-TPM protein indeed co-exist in skeletal muscle (predicted ratios are presented in supplementary 
table 3) where they interact with a range of other proteins to form the thin filament. Rather than exhaustively study 
different ratios of the tropomyosins, which in itself also present technical caveats due to an absence of troponins and other 
thin filament proteins specific to slow fibres, we chose to instead pursue single fibre contractility testing.  In this setting, the 
exact ratio of tropomyosin isoforms present in the patient fibres are studied in the setting of an intact contractile 
apparatus.  We felt this was a better approach to study how the mutant α-TPMslow impacted the contractile properties in 
the muscle fibres of affected patients.  
 
 
Minor comment (1): Have similar studies been performed for TPM2?  Do they provide any parallel insight or corroboration 
with the current data?  
 
Redress to minor comment (1): To our knowledge, no study has been performed for a large cohort of TPM2 patients 
studied collectively by one group using the same methodology. However, contractile mechanics have previously been 
assessed in TPM2 patients in a number of smaller studies yielding variable results: 
• TPM2 null and TPM2 E181K (Ochala et al, 2012): normal specific force in TPM2 null and E181K. TPM2 null showed 
decreased calcium sensitivity and normal Ktr while TPM2 E181K showed increased calcium sensitivity and reduced 
Ktr 
• TPM2 K7del (Mokbel et al, 2013): normal specific force, increased calcium sensitivity, reduced actin affinity. 
• TPM2 E41K (Ochala et al, 2008): normal specific force, lower Ktr and lower calcium sensitiviy 
• TPM2 R133W (Ochala et al, 2007): found lower specific force and lower Ktr but no difference in calcium sensitivity 
 
Based on these studies the contractile phenotype of TPM2-myopathy related mutations appears variable and is likely 
mutation specific. This is paralleled by TPM2 causing muscle weakness in some patients and a hypercontractile phenotype 
in others (Mokbel et al, 2013). In contrast, TPM3 has been associated only with muscle weakness to date and we observed a 
consistent reduction of force, Ktr and calcium sensitivity in our TPM3 cohort. I believe further studies of larger cohorts with 
all patients subject to the same testing regimes are needed to confirm if reduced Ca
2+
-sensitivity is a unifying feature of all 
TPM3 mutations, as this may be amenable to targeted therapy.  However, we concede it remains plausible and possible 
that specific mutations may either sensitise or desensitise the thin filament to Ca
2+
, or affect other thin filament properties 
that may similarly manifest as weakness in patients.  
 
 
Minor comment (2): Have the authors looks at α-actinin-3 expression in other forms of NM?  Is this a specific or non-
specific observation. 
 
Redress to minor comment (2): Our group has previously observed ectopic α-actinin-3 expression in ACTA1 nemaline 
myopathy patients. This finding has been published in (Ilkovski et al, 2001).  Patients with ACTA1 mutations I357L, G268C, 
and I136M had 90 %–100 % slow fibre predominance and abnormal expression of α-actinin-3 in a subset of slow fibres 
and/or fibres expressing both slow- and fast-myosin heavy chain. Below is a small panel showing ectopic a-actinin 3 
expression in a patient with an ACTA1 I136M mutation (Figure 1). Ectopic expression of α-actinin-3 is therefore not specific 
to disease caused by α-TPMslow mutations. Please note due to loss of α-actinin-3 resulting from a homozygous null mutation 
in 20 % of normal individuals (North et al, 1999) α-actinin-3 expression cannot be studied in all patients. 
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We added the following comment to paragraph 3 of the discussion in the manuscript: 
“Interestingly, similar ectopic expression of α-actinin-3 was previously observed in some patients with ACTA1 mutations 
(Ilkovski et al, 2001) and is thus not specific to TPM3-associated disease but could potentially be due to incomplete or 
abnormal fibre type conversion present in some myopathy patients.” 
 
 
Figure 1: Ectopic expression of fast fibre specific α-actinin-3 in slow fibres in a patient with the ACTA1 I136M mutation 
Consecutive muscle section stained with slow and fast myosin heavy chain (sMHC and fMHC, respectively) and α-actinin-3 
showing ectopic expression of α-actinin-3 in sMHC positive fibres (blue arrow). 
 
 
Minor comment (3): What do the authors make of their data vis-a-vis a strong contracture phenotype?  One hypothesis 
about this has been some element of hypercontractility exists (at least for TPM2).  Do you feel your data now "puts to rest" 
the idea that some TPM3 mutations are associated with hypercontraction?  And how does this compare to TPM2, where 
data (I believe from the authors group) has shown some mutations (TPM2del7K) do in fact cause hypercontractility under 
certain circumstances. 
 
Redress to minor comment (3): We believe our data conclusively shows that none of the mutations we investigated cause a 
hypercontractile phenotype. This topic is thoroughly discussed in the 6th paragraph of the discussion. A hypercontractile 
phenotype has been associated with the TPM2 K7del mutation (Mokbel et al, 2013) and it is likely that the effect on thin 
filament activation is highly dependent on the nature of the amino acid substitution, so mutation to mutation variability is 
expected. 
 
 
Reviewer: 2 
 
Comment (1): Please consider adapting or cross-referencing the new tropomyosin nomenclature. 
 
Redress to comment (1): We support adapting a universal nomenclature in order to allow clear distinction between the 
large number of tropomyosin proteins, so we cross referenced to the new nomenclature in the second paragraph of the 
introduction and have now also added a citation (Geeves et al, 2015). However, we believe for skeletal muscle the old 
nomenclature better reflects the expression patterns and properties of the three skeletal muscle tropomyosin isoforms and 
is thus easier to follow. We would prefer to maintain the old nomenclature for this manuscript but hope that cross-
referencing the new nomenclature at the start provides sufficient clarity. 
 
 
Comment (2): Was there any emerging correlation between the in vitro force measurements and the relative severities of 
the clinical phenotype? 
 
Redress to comment (2): Two out of three patients rated to have a moderate clinical presentation displayed the lowest 
specific forces measured in our cohort so there appears to be a correlation (see Table 2). However, unfortunately our cohort 
is not large enough to draw scientifically valid conclusions. Additionally, other factors may influence clinical severity as 
discussed above (Question 1, Reviewer 1) such as fibre typing in various muscle groups and slow fibre atrophy (e.g. smaller 
slow fibres will produce less force than bigger slow fibres; our force measurements do not reflect this as we normalise to 
cross sectional area). 
 
 
Comment (3): Was there any evidence that the state of S283 phosphorylation affected the measurements (I may have 
missed that)? 
 
Redress to comment (3): Phosphorylation at S283 is physiologically higher during development and decreases drastically in 
the first years of life (data not shown). Thus we were unable to interpret phosphorylation in young patients due to high 
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variability among patients and controls (N/D in Table 2). Most adult patients have a mild clinical phenotype. Low 
phosphorylation was detected in two patients, one was classified as mild and the other as moderate suggesting there is no 
correlation with clinical severity. As the cohort is not big enough to draw scientifically valid conclusions, and given 
phosphorylation at S283 is also altered and elevated in other forms of muscle disease, we do not think these data should be 
discussed further within manuscript. 
 
 
 
Table 2: Correlate clinical severity with contractile force and phosphorylation 
P Mutation in 
TPM3 
Age at 
biopsy 
Clinical 
classification 
Average force in slow 
fibres (mN/mm3 
S283 p 
1 K169E 16 m moderate 77.24±12.48 (type 1, n=2) 
52.17±13.74 (h/b, n=8) 
N/D 
2 R245G 20 m moderate 79.51±8.345 (type 1, n=2) 
105.5±25.16 (hybrid, n=6) 
N/D 
3a L100M 3 y mild 116.0±43 (type 1, n=9) N/D 
3b L100M 30 y mild 82.27±35.31 (type 1, n=16) +++ 
3c L100M 36 y mild 98.6±36.56 (type 1, n=15) +++ 
4 R168G 10 y mild 87.83±21.1 (type 1, n=12) N/D 
5 R168H  40 y mild 100.6±27.00 (type 1, n=14) N/D 
6a R168H 20 y mild N/D +++ 
6b R168H  56 y mild 105.8±49.51 (type 1, n=17) ++ 
7 R168C 3 y mild 89.37±27.18 (type 1, n=15) N/D 
8 R168C 19 y moderate 96.48±27.61 (type 1, n=4) + 
9 M9R 21 y mild N/D + 
10 R168H 53 y mild N/D ++ 
11 E241K 0.5y moderate N/D N/D 
12 R91P 0.5y severe N/D N/D 
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